

WO03070711

Publication Title:

OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS

Abstract:

Abstract of WO03070711

Compounds formula IA or IB, wherein W represents HOC=O-, HONHC=O- or HC= f6d ONOH- X represents -O- or -S- and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.

Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070711 A1

(51) International Patent Classification⁷: **C07D 271/06**,
285/08, 413/04, 413/06, A61K 31/4245, 31/433, A61P
29/00

[FR/FR]; 143, route des Crets, Collonge sous Saleve,
F-74160 (FR).

(21) International Application Number: PCT/GB03/00741

(74) Agent: **WALLS, Alan, James**; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 6LY (GB).

(22) International Filing Date: 20 February 2003 (20.02.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:
0204159.8 22 February 2002 (22.02.2002) GB

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (for all designated States except US):
BRITISH BIOTECH PHARMACEUTICALS LIMITED [GB/GB]; Watlington Road, Cowley, Oxford OX4 6LY (GB). **LABORATOIRES SERONO S.A.** [CH/CH]; Chateau de Vaumarcus, CH-2028 Vaumarcus (CH).


Published:

— with international search report


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS

WO 03/070711 A1



(IA)



(IB)

(57) Abstract: Compounds formula (IA) or (IB), wherein W represents HO(C=O)-, HONH(C=O)- or H(C=O)N(OH)-; X represents -O- or -S-; and R₁, R₂, and R₃ are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.

OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS

OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS

The present invention relates to therapeutically active hydroxamic and carboxylic acid derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in medicine. In particular, the compounds are inhibitors of matrix metalloproteinases.

Background to the Invention

The matrix metalloproteinases (MMP's) are a family of zinc containing endopeptidases which are capable of cleaving large biomolecules such as the collagens, proteoglycans and gelatins. Imbalance between active MMPs and endogenous inhibitors, leads to excessive tissue disruption. The three main groups of MMPs are the collagenases, the gelatinases, and the stromelysins. Collagenases include fibroblast collagenase (MMP-1), neutrophil collagenase (MMP-8), and collagenase 3 (MMP-13). Gelatinases include 72 kDa gelatinase (gelatinase A; MMP-2) and 92 kDa gelatinase (gelatinase B; MMP-9). Stromelysins include stromelysin 1 (MMP-3), stromelysin 2 (MMP-10) and matrilysin (MMP-7). However there are MMPs which do not fit neatly into the above groups, for example metalloelastase (MMP-12), membrane-type MMP (MT-MMP or MMP-14) and stromelysin 3 (MMP-11).

Over-expression and activation of MMPs have been linked with a wide range of diseases such as cancer; rheumatoid arthritis; osteoarthritis; chronic inflammatory disorders, such as asthma, bronchitis and emphysema; cardiovascular disorders, such as atherosclerosis; corneal ulceration; dental diseases such as gingivitis and periodontal disease; neurological disorders, such as multiple sclerosis and restenosis. For example, MMP-12 is required for the development of cigarette smoke-induced emphysema in mice, *Science*, 277, 2002 (1997). Inhibition of MMPs is therefore a strategy for treatment of such disease states. However, there is evidence that non-selective inhibition of matrix metalloproteinase activity may affect normal physiological process leading to dose limiting side effects. Selective

inhibition of MMP-12 and/or MMP-9 is thought to be a particularly relevant strategy for intervention in inflammatory conditions.

MMPs can hydrolyse the membrane-bound precursor of the pro-inflammatory cytokine tumour necrosis factor α (TNF- α). This cleavage yields mature soluble TNF- α and the inhibitors of MMPs can block production of TNF- α both in vitro and in vivo. This pharmacological action is a probable contributor to the anti-inflammatory action of this class of compounds.


For a recent review of MMP inhibition as reflected in the patent literature, see Doherty et. Al. Therapeutic Developments in Matrix Metalloproteinase Inhibition; Expert Opinions on Therapeutic Patents, 2002, 12, 665-707.

Brief Description of the Invention


The present invention provides a class of compounds which are inhibitors of MMPs. The class includes compounds which are selective inhibitors of MMP-12 relative to the collagenases and stromelysins. In addition, compounds of the invention can exhibit selective activity towards MMP-9. Compounds of the invention are therefore indicated for treatment of diseases primarily mediated by MMP-9 and/or MMP-12, especially inflammatory conditions such as multiple sclerosis and fibrosis.

Detailed Description of the Invention

According to the present invention there is provided compound formula (IA or (IB))



(IA)



(IB)

wherein

W represents HO(C=O)-, HONH(C=O)- or H(C=O)N(OH)-;

X represents -O- or -S-;

R₁ represents

hydrogen;

-OH or -SH;

fluoro or chloro;

-CF₃;

(C₁-C₆)alkyl;

(C₁-C₆)alkoxy;

(C₂-C₆)alkenyl;

phenyl or substituted phenyl;

phenyl (C₁-C₆)alkyl or substituted phenyl(C₁-C₆)alkyl;

phenyl (C₂-C₆)alkenyl or substituted phenyl(C₂-C₆)alkenyl

heterocyclyl or substituted heterocyclyl;

heterocyclyl(C₁-C₆)alkyl or substituted heterocyclyl(C₁-C₆)alkyl;

a group BSO_nA- wherein n is 0, 1 or 2 and B is hydrogen or a (C₁-C₆) alkyl, phenyl, substituted phenyl, heterocyclyl substituted heterocyclyl, (C₁-C₆)acyl, phenacyl or substituted phenacyl group, and A represents (C₁-C₆)alkylene;

-NH₂, (C₁-C₆)alkylamino or di(C₁-C₆)alkylamino;

amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, mercapto(C₁-C₆)alkyl or carboxy(C₁-C₆) alkyl wherein the amino-, hydroxy-, mercapto- or carboxyl-group are optionally protected or the carboxyl- group amidated; or

a cycloalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one or more substituents selected from C₁-C₆ alkyl, C₂-C₆ alkenyl, halo, cyano (-CN), -CO₂H, -CO₂R, -CONH₂, -CONHR, -CON(R)₂, -OH, -OR, oxo-, -SH, -SR, -

NHCOR, and -NHO₂R wherein R is C₁-C₆ alkyl or benzyl and/or (ii) fused to a cycloalkyl or heterocyclic ring;

R₂ represents a group R₁₀-(X)_n-(ALK)_m- wherein

R₁₀ represents hydrogen, or a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C₁-C₁₂)alkyl, (C₁-C₁₂)alkoxy, hydroxy, mercapto, (C₁-C₁₂)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, oxo, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₆)alkyl group and

ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S-linkages,

X represents -NH-, -O-, -S-, -NR^C or -NCOR^C wherein R^C is a (C₁-C₁₂)alkyl group and

m and n are independently 0 or 1;

R₃ represents the side chain of a natural or non-natural alpha amino acid;

R₄ represents optionally substituted

- C₁-C₆ alkyl,
- C₂-C₆ alkenyl,
- C₂-C₆ alkynyl,
- C₁-C₃ perfluoroalkyl,
- cycloalkyl,
- cycloalkyl(C₁-C₆ alkyl)-,
- cycloalkenyl,

cycloalkenyl(C₁-C₆ alkyl)-,
phenyl,
phenyl(C₁-C₆ alkyl)-,
naphthyl,
non-aryl heterocyclyl,
non-aryl heterocyclyl(C₁-C₆ alkyl)-,
heteroaryl; or
heteroaryl(C₁-C₆ alkyl)-;

and pharmaceutically acceptable salts hydrates and solvates thereof.

As used herein the term "(C₁-C₆)alkyl" means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein the term "divalent (C₁-C₆)alkylene radical" means a saturated hydrocarbon chain having from 1 to 6 carbon atoms and two unsatisfied valences.

As used herein the term "(C₂-C₆)alkenyl" means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

As used herein the term "divalent (C₂-C₆)alkenylene radical" means a hydrocarbon chain having from 2 to 6 carbon atoms, at least one double bond, and two unsatisfied valences.

As used herein the term "C₂-C₆ alkynyl" refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.

As used herein the term "divalent (C_2-C_6)alkynylene radical" means a hydrocarbon chain having from 2 to 6 carbon atoms, at least one triple bond, and two unsatisfied valences.

As used herein the term "cycloalkyl" means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein the term "cycloalkenyl" means an unsaturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. In the case of cycloalkenyl rings of from 5-8 carbon atoms, the ring may contain more than one double bond.

As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic group, and to groups consisting of two covalently linked monocyclic carbocyclic aromatic groups. Illustrative of such groups are phenyl, biphenyl and naphthyl.

As used herein the unqualified term "heterocycl" or "heterocyclic" includes "heteroaryl" as defined below, and in particular means a 5-8 membered aromatic or non-aromatic heterocyclic ring containing one or more heteroatoms selected from S, N and O, and optionally fused to a benzyl or second heterocyclic ring, and the term includes, for example, pyrrolyl, furyl, thienyl, piperidinyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, thiazepinyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, and benzimidazolyl rings.

As used herein the term "heteroaryl" refers to a 5- or 6- membered aromatic ring containing one or more heteroatoms, and optionally fused to a benzyl or pyridyl ring; and to groups consisting of two covalently linked 5- or 6-membered aromatic rings each containing one or more heteroatoms; and to groups consisting of a monocyclic carbocyclic aromatic group covalently

linked to a 5- or 6- membered aromatic rings containing one or more heteroatoms. Illustrative of such groups are thienyl, furyl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, pyrazolyl, isoazolyl, isothiazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, 4-([1,2,3]-thiadiazoly-4-yl)phenyl and 5-isoxazol-3-ylthienyl.

As used herein the unqualified term "carbocyclyl" or "carbocyclic" refers to a 5-8 membered ring whose ring atoms are all carbon.

Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four substituents, each of which independently may be (C₁-C₆)alkyl, phenyl, benzyl, (C₁-C₆)alkoxy, phenoxy, hydroxy, mercapto, (C₁-C₆)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, oxo, -COOH, -CONH₂, -COR^A, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₆)alkyl group. In the case where "substituted" means substituted by benzyl, the phenyl ring thereof may itself be substituted with any of the foregoing, except phenyl or benzyl.

As used herein the terms "side chain of a natural alpha-amino acid" and "side chain of a non-natural alpha-amino acid" mean the group R^X in respectively a natural and non-natural amino acid of formula NH₂-CH(R^X)-COOH.

Examples of side chains of natural alpha amino acids include those of alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, histidine, 5-hydroxylysine, 4-hydroxyproline, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, α -amino adipic acid, α -amino-n-butyric acid, 3,4-dihydroxyphenylalanine, homoserine, α -methylserine, ornithine, pipecolic acid, and thyroxine.

In natural alpha-amino acid side chains which contain functional substituents, for example amino, carboxyl, hydroxy, mercapto, guanidyl, imidazolyl, or indolyl groups as in arginine, lysine, glutamic acid, aspartic acid, tryptophan, histidine, serine, threonine, tyrosine, and cysteine, such functional substituents may optionally be protected.

Likewise, in the side chains of non-natural alpha amino acids which contain functional substituents, for example amino, carboxyl, hydroxy, mercapto, guanidyl, imidazolyl, or indolyl groups, such functional substituents may optionally be protected.

The term "protected" when used in relation to a functional substituent in a side chain of a natural or non-natural alpha-amino acid means a derivative of such a substituent which is substantially non-functional. The widely used handbook by T. W. Greene and P. G. Wuts "Protective Groups in Organic Synthesis" Second Edition, Wiley, New York, 1991 reviews the subject. For example, carboxyl groups may be esterified (for example as a C₁-C₆ alkyl ester), amino groups may be converted to amides (for example as a NHCOC₁-C₆ alkyl amide) or carbamates (for example as an NHC(=O)OC₁-C₆ alkyl or NHC(=O)OCH₂Ph carbamate), hydroxyl groups may be converted to ethers (for example an OC₁-C₆ alkyl or a O(C₁-C₆ alkyl)phenyl ether) or esters (for example a OC(=O)C₁-C₆ alkyl ester) and thiol groups may be converted to thioethers (for example a tert-butyl or benzyl thioether) or thioesters (for example a SC(=O)C₁-C₆ alkyl thioester).

There are at least two actual or potential chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such diastereoisomers and mixtures thereof. Currently, the preferred stereo configuration of the carbon atom carrying the R₂ group is R; that of the carbon atom carrying the R₁ group (when asymmetric) is R; and that of the carbon atom carrying the R₃ group (when asymmetric) is S.

The group R₁

R₁ may be, for example,

hydrogen, hydroxy, methyl, methoxy, trifluoromethyl, ethyl, n-propyl, allyl phenylpropyl, cyclopropylmethyl, phenylprop-2-enyl, thienylsulphanyl methyl, thienylsulphinylmethyl, or thienylsulphonylmethyl; or

C₁-C₄ alkyl, eg methyl, ethyl n-propyl or n-butyl, substituted by a phthalimido, 1,2-dimethyl-3,5-dioxo-1,2,4-triazolidin-4-yl, 3-methyl-2,5-dioxo-1-imidazolidinyl, 3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl, 2-methyl-3,5-dioxo-1,2,4-oxadiazol-4-yl, 3-methyl-2,4,5-trioxo-1-imidazolidinyl, 2,5-dioxo-3-phenyl-1-imidazolidinyl, 2-oxo-1-pyrrolidinyl, 2,5-dioxo-1-pyrrolidinyl or 2,6-dioxopiperidinyl, 5,5-dimethyl-2,4-dioxo-3-oxazolidinyl, hexahydro-1,3-dioxopyrazolo[1,2,a][1,2,4]-triazol-2-yl, or a naphththalimido (i.e. 1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl), 1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl, 1,3-dihydro-1,3-dioxo-2H-pyrrolo[3,4-b]quinolin-2-yl, or 2,3-dihydro-1,3-dioxo-1H-benz[d,e]isoquinolin-2-yl group; or

cyclohexyl, cyclooctyl, cycloheptyl, cyclopentyl, cyclobutyl, cyclopropyl, tetrahydropyranyl or morpholinyl.

Presently preferred R₁ groups include hydrogen, hydroxy, methoxy, cyclopentyl, n-propyl, and allyl. Of these, hydrogen, hydroxy, methoxy and allyl are presently more preferred.

The group R₂

R₂ may for example be

C₁-C₁₂ alkyl, C₃-C₆ alkenyl or C₃-C₆ alkynyl;

cycloalkyl(C₁-C₆ alkyl)-;

phenyl(C₁-C₆ alkyl)-, phenyl(C₃-C₆ alkenyl)- or phenyl(C₃-C₆ alkynyl)- optionally substituted in the phenyl ring;

heteroaryl(C₁-C₆ alkyl)-, heteroaryl(C₃-C₆ alkenyl)- or heteroaryl(C₃-C₆ alkynyl)- optionally substituted in the heteroaryl ring;

4-phenylphenyl(C₁-C₆ alkyl)-, 4-phenylphenyl(C₃-C₆ alkenyl)-, 4-phenylphenyl(C₃-C₆ alkynyl)-, 4-heteroarylphenyl(C₁-C₆ alkyl)-, 4-heteroarylphenyl(C₃-C₆ alkenyl)-, 4-heteroarylphenyl(C₃-C₆ alkynyl)-, optionally substituted in the terminal phenyl or heteroaryl ring;

phenoxy(C₁-C₆ alkyl)- or heteroaryloxy(C₁-C₆ alkyl)- optionally substituted in the phenyl or heteroaryl ring;

Specific examples of such groups include methyl, ethyl, n- or iso-propyl, n-, iso- or tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-nonyl, n-decyl, prop-2-yn-1-yl, cyclohexylethyl, cyclopentylmethyl, 3-phenylprop-2-yn-1-yl, 3-(2-chlorophenyl)prop-2-yn-1-yl, benzyl phenylpropyl, 4-chlorophenylpropyl, 4-methylphenylpropyl, 4-methoxyphenylpropyl, phenoxybutyl, 3-(4-pyridylphenyl)propyl-, 3-(4-(4-pyridyl)phenyl)prop-2-yn-1-yl, 3-(4-phenylphenyl)propyl-, 3-(4-phenyl)phenyl)prop-2-yn-1-yl and 3-[(4-chlorophenyl)phenyl]propyl-.

Presently preferred R₂ groups include benzyl, n-butyl, iso-butyl, n-hexyl, ethoxyphenylpropyl, preferably 4-ethoxyphenylpropyl and cyclopentylmethyl. Of these, isobutyl and ethoxyphenylpropyl, particularly 4-ethoxyphenylpropyl, are presently more preferred.

The group R₃

R₃ may for example be C₁-C₆ alkyl, phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 2-, 3-, or 4-hydroxyphenyl, 2-, 3-, or 4-methoxyphenyl, 2-, 3-, or 4-pyridylmethyl, benzyl, 2-, 3-, or 4-hydroxybenzyl, 2-, 3-, or 4-benzoyloxybenzyl, 2-, 3-, or 4-C₁-C₆ alkoxybenzyl, or benzyloxy(C₁-C₆alkyl)-; or

the characterising group of a natural α -amino acid, in which any functional group may be protected, any amino group may be acylated and any carboxyl group present may be amidated; or

a group $-[\text{Alk}]_n\text{R}_6$ where Alk is a (C_1-C_6)alkyl or (C_2-C_6)alkenyl group optionally interrupted by one or more -O-, or -S- atoms or -N(R_7)-groups [where R_7 is a hydrogen atom or a (C_1-C_6)alkyl group], n is 0 or 1, and R_6 is an optionally substituted cycloalkyl or cycloalkenyl group; or

a benzyl group substituted in the phenyl ring by a group of formula $-\text{OCH}_2\text{COR}_8$ where R_8 is hydroxyl, amino, (C_1-C_6)alkoxy, phenyl(C_1-C_6)alkoxy, (C_1-C_6)alkylamino, di((C_1-C_6)alkyl)amino, phenyl(C_1-C_6)alkylamino, the residue of an amino acid or acid halide, ester or amide derivative thereof, said residue being linked via an amide bond, said amino acid being selected from glycine, \square or \square alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid, and aspartic acid; or

a heterocyclic(C_1-C_6)alkyl group, either being unsubstituted or mono- or di-substituted in the heterocyclic ring with halo, nitro, carboxy, (C_1-C_6)alkoxy, cyano, (C_1-C_6)alkanoyl, trifluoromethyl (C_1-C_6)alkyl, hydroxy, formyl, amino, (C_1-C_6)alkylamino, di-(C_1-C_6)alkylamino, mercapto, (C_1-C_6)alkylthio, hydroxy(C_1-C_6)alkyl, mercapto(C_1-C_6)alkyl or (C_1-C_6)alkylphenylmethyl; or

a group $-\text{CR}_a\text{R}_b\text{R}_c$ in which:

each of R_a , R_b and R_c is independently hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl(C_1-C_6)alkyl, (C_3-C_8)cycloalkyl; or

R_c is hydrogen and R_a and R_b are independently phenyl or heteroaryl such as pyridyl; or

R_c is hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, or (C₃-C₈)cycloalkyl, and R_a and R_b together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 5- to 6-membered heterocyclic ring; or

R_a, R_b and R_c together with the carbon atom to which they are attached form a tricyclic ring (for example adamantyl); or

R_a and R_b are each independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, or a group as defined for R_c below other than hydrogen, or R_a and R_b together with the carbon atom to which they are attached form a cycloalkyl or heterocyclic ring, and R_c is hydrogen, -OH, -SH, halogen, -CN, -CO₂H, (C₁-C₄)perfluoroalkyl, -CH₂OH, -CO₂(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -O(C₂-C₆)alkenyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -SO₂(C₁-C₆)alkyl, -S(C₂-C₆)alkenyl, -SO(C₂-C₆)alkenyl, -SO₂(C₂-C₆)alkenyl or a group -Q-W wherein Q represents a bond or -O-, -S-, -SO- or -SO₂- and W represents a phenyl, phenylalkyl, (C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkylalkyl, (C₄-C₈)cycloalkenyl, (C₄-C₈)cycloalkenylalkyl, heteroaryl or heteroarylalkyl group, which group W may optionally be substituted by one or more substituents independently selected from, hydroxyl, halogen, -CN, -CO₂H, -CO₂(C₁-C₆)alkyl, -CONH₂, -CONH(C₁-C₆)alkyl, -CONH(C₁-C₆alkyl)₂, -CHO, -CH₂OH, (C₁-C₄)perfluoroalkyl, -O(C₁-C₆)alkyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -SO₂(C₁-C₆)alkyl, -NO₂, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NHCO(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, phenyl or benzyl.

Examples of particular R₃ groups include benzyl, phenyl, cyclohexylmethyl, pyridin-3-ylmethyl, tert-butoxymethyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, 1-benzylthio-1-methylethyl, 1-methylthio-1-methylethyl, and 1-mercaptop-1-methylethyl.

Presently preferred R₃ groups include phenyl, benzyl, tert-butoxymethyl, iso-propyl, tert-butyl, and iso-butyl. Of these, tert-butyl and benzyl are presently more preferred.

The group R₄

R₄ may be, for example, (C₁-C₆)alkyl such as methyl, ethyl, n- or iso-propyl, prop-2-yl, and tert-butyl; (C₃-C₈)cycloalkyl such as cyclopropyl or cyclopentyl; phenyl; phenyl(C₁-C₆alkyl)- such as benzyl; heteroaryl(C₁-C₆alkyl)- such as thienylmethyl; monocyclic heterocyclic such as morpholino; or monocyclic heteroaryl such as thienyl or furanyl. Any of the foregoing may optionally be substituted, for example by methyl, trifluoromethyl, hydroxy, mercapto, amino or carboxy.

As mentioned above, the present compounds are useful in human or veterinary medicine since they are active as inhibitors of MMPs. Accordingly in another aspect, this invention concerns:

- (i) a method of management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective amount of a compound which is a member of the group defined above, or a pharmaceutically acceptable salt thereof; and
- (ii) a compound which is a member of the group defined above, for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by MMP; and

(iii) the use of a compound which is a member of the group defined above in the preparation of an agent for the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by MMPs.

Diseases or conditions mediated by MMPs include those involving tissue breakdown such as bone resorption, inflammatory diseases, dermatological conditions and tumour growth or invasion by secondary metastases; in particular rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis; restenosis, emphysema, bronchitis and asthma.

In a further aspect of the invention there is provided a pharmaceutical or veterinary composition comprising a compound which is a member of the group defined above together with a pharmaceutically or veterinarily acceptable excipient or carrier.

It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Optimum dose levels and frequency of dosing will be determined by clinical trial.

The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica;


disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.

For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.

The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.

Compounds according to the present invention in which W is a hydroxamic acid group $\text{HONH}(\text{C=O})$ - may be prepared from corresponding compounds of the invention in which W is a carboxyl group -COOH or from the corresponding protected hydroxamic acid derivatives. That process, which forms another aspect of the invention, comprises causing an acid of general formula (IIA) or (IIB)



or an activated derivative thereof to react with hydroxylamine, O-protected hydroxylamine, or an N,O-diprotected hydroxylamine, or a salt thereof, X, R₁, R₂, R₃, and R₄ being as defined in general formula (IA) or (IB) except that any substituents in R₁, R₂, R₃, and R₄ which are potentially reactive with hydroxylamine, O-protected hydroxylamine, the N,O-diprotected hydroxylamine or their salts may themselves be protected from such reaction, then removing any protecting groups from the resultant hydroxamic acid moiety and from any protected substituents in R₁, R₂, R₃, and R₄.

Conversion of (IIA) or (IIB) to an activated derivative such as the pentafluorophenyl, hydroxysuccinyl, or hydroxybenzotriazolyl ester may be effected by reaction with the appropriate alcohol in the presence of a dehydrating agent such as dicyclohexyl carbodiimide (DCC), N,N-dimethylaminopropyl-N-ethyl carbodiimide (EDC), or 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ).

Protecting groups as referred to above are well known per se, for example from the techniques of peptide chemistry. Amino groups are often protectable by benzoyloxycarbonyl, t-butoxycarbonyl or acetyl groups, or in the form of a


phthalimido group. Hydroxy groups are often protectable as readily cleavable ethers such as the t-butyl or benzyl ether, or as readily cleavable esters such as the acetate. Carboxy groups are often protectable as readily cleavable esters, such as the t-butyl or benzyl ester.

Examples of O-protected hydroxylamines for use in method (a) above include O-benzylhydroxylamine, O-4-methoxybenzylhydroxylamine, O-trimethylsilylhydroxylamine, and O-tert-butoxycarbonylhydroxylamine.


Examples of O,N-diprotected hydroxylamines for use in method (a) above include N,O-bis(benzyl)hydroxylamine, N,O-bis(4-methoxybenzyl)hydroxylamine, N-tert-butoxycarbonyl-O-tert-butyldimethylsilylhydroxylamine, N-tert-butoxycarbonyl-O-tetrahydropyranylhydroxylamine, and N,O-bis(tert-butoxycarbonyl)hydroxylamine.

Compounds of the invention wherein W is an N-formylhydroxylamino group H(C=O)NH(OH)- may be prepared by N-formylation of the corresponding O-protected compound in which W is -NH(OH), then removal of the O-protecting group.

Compounds according to the present invention in which W is a carboxylic acid group -COOH, ie compounds of formula (IIA) or (IIB) above, may be prepared by a process comprising: coupling an acid of formula (III) or an activated derivative thereof



with an amine of formula (IVA) or (IVB)



wherein X, R₁ R₂, R₃, and R₄ are as defined in general formula (IA) and (IB) except that any substituents in R₁, R₂, R₃, and R₄ which are potentially reactive in the coupling reaction may themselves be protected from such reaction, and R₁₁ represents a hydroxy protecting group, and subsequently removing the protecting group R₁₁ and any protecting groups from R₁ R₂, R₃, and R₄.

Active derivatives of acids (III) include activated esters such as the pentafluorophenyl ester, acid anhydrides and acid halides, eg chlorides. Suitable hydroxy protecting groups may be selected from those known in the art.

Compounds of formula (IVA) and (IVB) may be prepared by methods analogous to the general methods for oxadiazole ring formation illustrated in Schemes 1 and 2 in Examples 1 and 2 below.

The following preparative Examples describe the preparation of compounds useful in accordance with the invention.

The following abbreviations have been used in the examples

DCM - Dichloromethane

DMF - N,N-Dimethylformamide

HOBT - 1-Hydroxybenzotriazole


Pfp – Pentafluorophenol

WSCDI - N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride


HCl - Hydrochloric acid
THF – Tetrahydrofuran
TFA – Trifluoroacetic acid
 $\text{P}(\text{O-Tol})_3$ – Tri-O-tolylphosphine
AcOEt – Ethyl acetate
 CH_3CN - Acetonitrile

Example 1

3R-[2,2-Dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanohydroamic acid.



Scheme 1.



Reagents and conditions. A. HOBT, WSC, NH₃, DMF. B. POCl₃, pyridine. C. Aq.NH₂OH,ethanol, 70°C. D. RCOCl, DMAP, pyridine, DMF, 100°C. E. HBr/acetic acid. F. chiral succinate, DMF. G. Aq.NH₂OH, methanol. H. Pfp, WSC, DMF. I. 1M HCl, THF.

Example 1 was prepared as outlined in Scheme 1 using procedures described below.

Step A. (1S-carbamoyl-2,2-dimethyl-propyl)-carbamic acid benzyl ester

N-benzyloxycarbonyl-L-*tert*-butylglycine (50g, 189mmol) was dissolved in DMF (500mL) and cooled in an ice-water bath before addition of HOBT (28.05g, 208mmol) and WSCDI (39.8g, 208mmol). Reaction was stirred at 0°C for 1 hour before addition of 0.880 ammonia solution (21ml, 377mmol). The reaction was allowed to warm to room temperature and stirred for 18 hours. DMF was removed under reduced pressure and the residue partitioned between ethyl acetate and 1M HCl. The organic layer was separated and washed with 1M HCl, saturated aqueous sodium bicarbonate solution and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure to yield (1S-carbamolyl-2,2-dimethyl-propyl)-carbamic acid benzyl ester as a white solid (44.1g, 89%).
1H-NMR; delta (CDCl₃), 7.32 (5H, m), 6.05 (1H, bs), 5.71 (1H, bs), 5.60 (1H, d, J = 6.5Hz), 5.08 (2H, s), 4.01 (1H, d, J = 6.5Hz) and 1.00 (9H, s).
LRMS; +ve ion 265 (M+H), 287 (M+Na).

Step B. (1S-cyano-2,2-dimethyl-propyl)-carbamic acid benzyl ester

(1S-carbamolyl-2,2-dimethyl-propyl)-carbamic acid benzyl ester (44.1g, 167mmol) was dissolved in anhydrous pyridine (203ml, 2.5mol) under an inert atmosphere and cooled in an ice-water bath. Phosphorus oxychloride (21.8ml, 234mmol) was added slowly over 15 minutes and the reaction allowed to stir in the ice-water bath for 2 hours before warming to room temperature and stirred for 12 hours. The reaction mixture was treated with ice-water (400ml) and extracted with ethyl acetate (2 x 300ml). The organic layer was separated and washed with 1M HCl, saturated aqueous sodium bicarbonate solution and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure. Column chromatography on silica gel using ethyl

acetate/hexane as eluent leads to isolation of the desired product as an orange oil (36.72g, 89%).

1H-NMR; delta (CDCl₃), 7.42 (5H, m), 5.28 (2H, m), 4.55 (2H, d, J = 6.5Hz) and 1.11 (9H, s),

LRMS; +ve ion 269 (M+Na), 247.2 (M+H),

Step C. [1S-(N-hydroxycarbamimidoyl)-2,2-dimethyl-propyl]-carbamic acid benzyl ester

(1S-cyano-2,2-dimethyl-propyl)-carbamic acid benzyl ester (37.60g, 153mmol) was dissolved in ethanol (300ml) and treated dropwise with 50% aqueous hydroxylamine (51ml, 764mmol). The reaction was heated to reflux and stirred for 3 hours. The reaction was then cooled and concentrated under reduced pressure to yield the desired product as a white foam/gum (41.5g, 97%).

1H-NMR; delta (CDCl₃), 7.32 (5H, m), 6.21 (1H, bs), 5.95 (1H, bs), 5.81 (1H, d, J = 6.4Hz), 5.08 (2H, m), 4.79 (1H, bs), 4.05 (1H, d, J = 6.5Hz) and 0.95 (9H, s).

LRMS; +ve ion 279.8 (M+H).

Step D. [2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-carbamic acid benzyl ester

[1S-(N-hydroxycarbamimidoyl)-2,2-dimethyl-propyl]-carbamic acid benzyl ester (0.21g, 0.75mmol) was dissolved in DMF (5mL) and treated with pyridine (0.1ml, 1.28mmol), benzoyl chloride (0.13ml, 1.1mmol) and DMAP (catalytic). The reaction mixture was stirred at room temperature for 4 hour before heating to 100°C and stirring for 16 hours. The reaction was cooled back to room temperature and concentrated under reduced pressure. The reaction was diluted with ethyl acetate and washed with 1M HCl, saturated aqueous sodium bicarbonate solution and brine before drying over

magnesium sulphate, filtration and concentration under reduced pressure.

The desired product was isolated as an orange oil (0.22g, 78%).

1H-NMR; delta (CDCl₃), 8.12 (2H, m), 7.55 (3H, m), 7.32 (5H, m), 5.55 (1H, d, J = 6.4Hz), 5.12 (2H, m), 4.95 (1H, d, J = 6.5Hz) and 1.10 (9H, s).

LRMS; +ve ion 366.2 (M+H), 388.2 (M+Na).

Step E. 2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylamine

[2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-carbamic acid benzyl ester (0.2g, 0.5mmol) was treated with 48% hydrobromic acid in acetic acid (10ml). The reaction mixture was stirred at room temperature for 3 hours. The reaction was concentrated under reduced pressure and partitioned between ethyl acetate and 1M Na₂CO₃. The organic layer was further washed with 1M Na₂CO₃ and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure. The product was isolated as a yellow oil (0.13g, 98%).

LRMS; +ve ion 232 (M+H).

Step F. 2R-(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid [2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-amide

2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylamine (0.13g, 0.6mmol) was dissolved in DMF (5ml) and cooled in an ice-water bath before the addition 2R-(2,2-Dimethyl-5S-oxo-[1,3]dioxolan-4-yl)-4-methyl-pentanoic acid pentafluorophenyl ester (0.22g, 0.6mmol). Reaction was allowed to warm to room temperature and stirred for 15 hours. The DMF was removed under reduced pressure and the reaction diluted with ethyl acetate and washed with 1M HCl, saturated aqueous sodium bicarbonate solution and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure. Column chromatography on silica gel using ethyl acetate and hexane (1:1) lead to isolation of the desired product as a white solid (0.16g, 64%).

1H-NMR; delta (CDCl₃), 8.12 (2H, m), 7.55 (3H, m), 6.65 (1H, d, J = 6.4Hz), 5.25 (1H, d, J = 6.5Hz), 4.55 (1H, d, J = 5.9Hz), 2.75 (1H, m), 1.64 (3H, s), 1.55 (3H, s), 1.04 (9H, s) and 0.88 (6H, m).
LRMS; +ve ion 444 (M+H).

Step G. 3R-[2,2-Dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanohydroxamic acid

2R-(2,2-Dimethyl-5S-oxo-[1,3]dioxolan-4-yl)-4-methyl-pentanoic acid [2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-amide (0.05g, 0.11mmol) was dissolved in methanol (2ml) and treated with 50% aqueous hydroxylamine (0.04ml, 0.5mmol). Reaction was stirred at room temperature for 2 hours before evaporation under reduced pressure. The reaction product was separated by preparative reverse phase chromatography to yield the required product as a white solid (0.02g, 44%).

1H-NMR; delta (CH₃OD), 8.13 (2H, m), 7.65 (1H, m), 7.58 (2H, m), 5.14 (1H, s), 4.01 (1H, d, J=7.1Hz), 2.94 (1H, m), 1.60 (1H, m), 1.45 (1H, m), 1.16 (1H, m), 1.07 (9H, s), 0.89 (3H, d, J = 6.5Hz) and 0.86 (3H, d, J = 6.6Hz).

13 C-NMR; delta (CH₃OD), 177.1, 176.3, 172.0, 171.6, 134.6, 130.8, 129.4, 125.7, 73.7, 55.8, 49.6, 39.7, 36.2, 27.4, 27.2, 24.2 and 22.5.

LRMS; +ve ion 419 (M+H); -ve ion 417 (M-H).


Step H. 2R-(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid pentafluorophenyl ester

2R-(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid (prepared according to WO 94/02447) (30g, 130mmol) was dissolved in ethyl acetate (300ml) and treated with pentafluorophenol (28.8g, 156mmol) and WSCDI (30g, 156mmol). Reaction was heated to reflux for 2 hours and then allowed to stir at room temperature for 12 hours. The reaction mixture was washed with 1M Na₂CO₃ and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure. The product was

recrystallised from ethyl acetate/hexane to yield the desired product as a single diastereomer (21.2g, 42%).

¹H-NMR; delta (CDCl₃), 4.55 (1H, d, J = 6.7Hz), 3.31 (1H, m), 1.85 (3H, bm), 1.65 (3H, s), 1.58 (3H, s), 1.05 (3H, d, J = 6.5Hz) and 0.99 (3H, d, J = 6.5Hz).

Also prepared, the diastereomer 3R-[2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-2R-hydroxy-5-methylhexanohydroxamic acid.



M+H = 420.0, M+Na = 441.5, M-H = 417.5.

The corresponding carboxylic acid was prepared as outlined in Scheme 1 and the procedure below.


Step I. 3R-[1S-(5-Furan-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanoic acid

2R-(2,2-Dimethyl-5S-oxo-[1,3]dioxolan-4-yl)-4-methyl-pentanoic acid [2,2-dimethyl-1S-(5-Furan-2-yl-[1,2,4]oxadiazol-3-yl)-propyl]-amide (0.05g, 0.12mmol) was dissolved in tetrahydrofuran (5ml) and cooled to 4 °C during the addition of 1M hydrochloric acid (5ml). The solution was allowed to warm to room temperature and then stirred for 18 hours. The bulk of the solvent was removed under reduced pressure before drying under high vacuum to a white foam (0.045g, ca. quant.).


1H-NMR; delta (CH₃OD), 7.88 (1H, s), 7.45 (1H, d, J = 3.6Hz), 6.74 (1H, m), 5.15 (1H, s), 4.18 (2H, d, J = 6.4Hz), 2.91 (1H, m), 1.65 (1H, m), 1.50 (1H, m), 1.31 (1H, m), 1.06 (9H, s), 0.88 (3H, d, J = 6.4Hz) and 0.82 (3H, d, J = 6.5Hz). LRMS; -ve ion 392.2 (M-H).

Example 2

3R-[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanohydroxamic acid



Scheme 2.



Reagents and conditions. A. HOBT, WSCDI, DMF. B. Toluene, 100°C. C. Aq.NH₂OH, ethanol, 70°C. D. TFA, DCM. E. HOBT, WSCDI, DMF. F. Aq.NH₂OH, methanol.

Example 2 was prepared as outlined in scheme 2 using procedures described below.

Step A. 2S-*tert*-Butoxycarbonylamino-3,3-dimethyl-butyric acid benzotriazol-1-yl ester

A solution of N-*tert*-Butoxycarbonyl-L-*tert*-butyl glycine (5g, 21.6mmol) in ethyl acetate (80mL) was cooled in an ice-water bath. HOBT (3.22g, 23.8mmol) and WSCDI (4.56g, 23.8mmol) were added and the reaction allowed to stir at room temperature for 12 hours. The reaction mixture was washed with 1M Na₂CO₃ and brine, before drying over magnesium sulphate, filtration and concentration to a white foam (5.74g, 76%).

1H-NMR; delta (CDCl₃), 8.05 (1H, m), 7.65 (2H, m), 7.41 (1H, m), 5.10 (1H, d, J = 6.7Hz), 4.45 (1H, d, J = 6.5Hz), 1.55 (9H, s) and 1.21 (9H, s).

LRMS; +ve ion 349 (M+H).

Step B. [2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-carbamic acid *tert*-butyl ester

2S-*tert*-Butoxycarbonylamino-3,3-dimethyl-butyric acid benzotriazol-1-yl ester (3.71g, 10.7mmol) was dissolved in toluene (80mL) and treated with N-hydroxy-benzamidine (2.9g, 21.3mmol). The reaction mixture was stirred at 110°C for 18 hours. The solution was concentrated under reduced pressure and partitioned between ethyl acetate and 1M Na₂CO₃. The organic layer was further washed with 1M Na₂CO₃ and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure. Column chromatography on silica gel using ethyl acetate and hexane (1:4) lead to isolation of the desired product (2.58g, 73%).

1H-NMR; delta (CDCl₃), 8.10 (2H, m), 7.50 (3H, m), 5.30 (1H, bd), 4.95 (1H, d, J = 6.5Hz), 1.44 (9H, s) and 1.03 (9H, s).

LRMS; +ve ion 354.2 (M+Na).

Step C. N-hydroxy-benzamidine

Benzonitrile (5g, 48mmol) was dissolved in ethanol (100ml) and treated with 50% aqueous hydroxylamine (16ml, 242mmol). Reaction was heated to reflux for 3 hours before concentration under reduced pressure to give a clear foam (4.5g, 68%).

LRMS; +ve ion 137 (M+H).

Step D. 2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylamine

[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-carbamic acid *tert*-butyl ester (1g, 3.0mmol) was dissolved in DCM (5ml) and treated with TFA (5ml). Reaction stirred at room temperature for 3 hours. The reaction was concentrated under reduced pressure and partitioned between ethyl acetate and 1M Na₂CO₃. The organic layer was further washed with 1M Na₂CO₃ and brine before drying over magnesium sulphate, filtration and concentration under reduced pressure to give the desired product (0.65g, 93%).

1H-NMR; delta (CH₃OD), 8.10 (2H, m), 7.55 (3H, m), 4.81 (1H, s) and 1.19 (9H, s).

LRMS; +ve ion 232 (M+H).

Step E. 2R-(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid-[2,2-dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-amide

2R-(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid (0.27g, 1.17mmol) was dissolved in DMF (5ml) and cooled in an ice-water bath before addition of HOBT (0.17g, 1.29mmol) and WSCDI (0.25g, 1.29mmol). Reaction was stirred at 0°C for 1 hour before addition of 2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylamine (0.3g, 1.29mmol). The reaction was allowed to warm to room temperature and stirred for 18 hours. DMF was removed under reduced pressure and the residue partitioned between ethyl acetate and 1M HCl. The organic layer was separated and washed with 1M HCl, saturated aqueous sodium bicarbonate solution and brine before drying over magnesium sulphate, filtration and concentration under reduced

pressure. Column chromatography on silica gel using ethyl acetate and hexane (1:4) lead to isolation of the desired product (0.26g, 46%).
1H-NMR; delta (CDCl₃), 8.10 (2H, m), 7.50 (3H, m), 6.80 (1H, d, J = 9.3Hz), 5.24 (1H, d, J = 9.3Hz), 4.55 (1H, d, J = 5.1Hz), 2.81 (1H, m), 1.63 (3H, s), 1.55 (3H, s), 0.92 (3H, d, J = 6.1Hz) and 0.89 (3H, d, J = 6.2Hz).
LRMS; +ve ion 444 (M+H).

Step F. 3R-[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanohydroxamic acid

2R-(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-4-methyl-pentanoic acid [2,2-dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-amide (0.26g, 0.6mmol) was dissolved in methanol (5ml) and treated with 50% aqueous hydroxylamine (0.2ml, 2.95mmol). Reaction stirred at room temperature for 3 hrs before concentration under reduced pressure. The product was recrystallised from ethyl acetate/hexane to yield the desired product (0.11g, 41%).


1H-NMR; delta(CH₃OD), 8.06 (2H, m), 7.53 (3H, m), 5.21 (1H, s), 4.01 (1H, d, J=7.5Hz), 2.99 (1H, m), 1.60 (1H, m), 1.50 (1H, m), 1.15 (1H, m), 1.10 (9H, s), 0.92 (3H, d, J = 6.6Hz) and 0.81 (3H, d, J = 6.5Hz).

13 C-NMR; delta (CH₃OD), 180.3, 176.7, 172.0, 169.7, 132.9, 130.5, 128.8, 128.4, 73.7, 57.1, 49.5, 39.5, 36.5, 27.3, 24.3 and 22.5.


LRMS; +ve ion 419 (M+H); -ve ion 417 (M-1).

Example 3:

2R-[3-(4-Ethoxy-phenyl)-propyl]-N₁-[1S-(5-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,2-dimethyl-propyl]-3S,N₄-dihydroxy-succinamide



Scheme 3.



Reagents and conditions. A: LiHMDS, AlBr, THF, -78 to RT; B: 4-OEt-phenylBr, P(o-Tol)₃, Pd(OAc)₂, NEt₃, CH₃CN; C: 10%Pd/C, H₂, MeOH; D: LiOH, MeOH, H₂O; E: CuCl₂, dimethoxyacetone, acetone; F: pentafluorophenol, WSC, HOAt, CH₂Cl₂; G: Amine (as detailed in Step E, Scheme 1), DMF; H: aq.NH₂OH, iPrOH

Example 3 was prepared as outlined in Scheme 3 using procedures described below.

Step A: 2R-allyl-3S-hydroxy-succinic acid diisopropylester.

To a cold (-78C) solution of 2S-Hydroxy-succinic acid diisopropyl ester (19.70 ml, 95 mmol) in THF (35 ml) was added LiHMDS (200 ml, 0.2 mol, 2.1 eq.) dropwise. The reaction mixture was stirred at -78C for two hours and then at -30C for 30 min. The reaction mixture was then cooled to -78C and allyl bromide (12.36 ml, 0.14 mol, 1.5 eq.) was added dropwise. The reaction mixture was allowed to warm to RT overnight. It was poured into a saturated solution of NH₄Cl/ice (200 ml). Extraction with AcOEt (3 X 200 ml) followed by a wash with water (50 ml) and with brine (50 ml) afforded a yellow oil after removal of the solvents under vacuum. Purification by flash chromatography gave 2R-allyl-3S-hydroxy-succinic acid diisopropylester as a colourless oil (7.76 g, de = 80%, 40% yield).

1H-NMR; delta (CDCl₃), 5.77-5.88 (1H, m), 4.98-5.21 (4H, m), 4.22 (1H, brs), 3.18 (1H, bs), 2.87-2.94 (1H, m), 2.56-2.65 (1H, m), 2.40-2.48 (1H, m), 1.29 (6H, d, J = 6.3 Hz) and 1.22 (6H, d, J = 6.3 Hz).

LRMS: +ve ion 281 (M+Na).

Step B: 2R-[3-(4-ethoxy-phenyl)-allyl]-3S-hydroxy-succinic acid diisopropyl ester.

To a solution of 2R-allyl-3S-hydroxy-succinic acid diisopropylester (4.79 g, 18.5 mmol), 4-bromo phenetole (3.19 ml, 22.2 mmol, 1.2 eq.) and NEt₃ (6.22 ml, 44.6 mmol, 2.4 eq.) in CH₃CN (40 ml), was added a sonicated (for 2 min) suspension of P(O-Tol)₃ (0.57 g, 2.22 mmol, 0.1 eq.) and Pd(OAc)₂ (209 mg, 5%) in CH₃CN (5 ml). The reaction mixture was heated to reflux for 2 hrs. CH₃CN was removed under vacuum. The crude was extracted with AcOEt (3 X 200 ml), washed with water (50 ml) and with brine (50 ml). A purification by flash chromatography afforded the desired 2R-[3-(4-ethoxy-phenyl)-allyl]-3S-hydroxy-succinic acid diisopropyl ester (5.92 g, 84% yield).

1H-NMR; delta (CDCl_3), 7.28 (2H, d, $J = 8.8\text{Hz}$), 6.83 (2H, d, $J = 8.8\text{Hz}$), 6.46 (1H, d, $J = 15.7\text{Hz}$), 6.02-6.12 (1H, m), 4.98-5.13 (2H, m), 4.26 (1H, dd, $J = 7.1, 3.0\text{Hz}$), 4.02 (2H, q, $J = 7.0\text{Hz}$), 3.23 (1H, d, $J = 7.1\text{Hz}$), 2.92-2.97 (1H, m), 2.68-2.79 (1H, m), 2.49-2.62 (1H, m), 1.41 (3H, t, $J=7.0\text{ Hz}$) and 1.19-1.30 (12H, m).

LRMS: +ve ion 400 ($M+\text{Na}$).

Step C: 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid diisopropyl ester.

To a solution of 2R-[3-(4-ethoxy-phenyl)-allyl]-3S-hydroxy-succinic acid diisopropyl ester (129 mg, 0.34 mmol) in MeOH (10 ml) under an inert atmosphere, was added 10%Pd/C (13 mg). H₂ was bubbled through the resulting suspension for 30 min. The reaction mixture was then stirred under 1 atmosphere of H₂ for 16 hrs. Pd/C was filtered off and the solvent removed under reduced pressure to give 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid diisopropyl ester (115 mg, 88% yield).

1H-NMR; delta (CDCl_3), 7.08 (2H, d, $J = 8.6\text{Hz}$), 6.81 (2H, d, $J = 8.6\text{Hz}$), 4.97-5.14 (2H, m), 4.20 (1H, dd, $J = 7.3, 3.5\text{Hz}$), 4.01 (2H, q, $J = 7.0\text{Hz}$), 3.18 (1H, d, $J = 7.3\text{Hz}$), 2.77-2.83 (1H, m), 2.55-2.62 (2H, m), 1.45-1.94 (4H, m), 1.40 (3H, t, $J = 7.0\text{Hz}$) and 1.12-1.30 (12H, m).

LRMS: +ve ion 402.0 ($M+\text{Na}$).

Step D: 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid.

To a solution of 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid diisopropyl ester (4.78 g, 12.6 mmol) in THF/water (3:1, 120 ml) was added NaOH (1.66 g, 41.5 mmol, 5.5 eq.). The reaction mixture was then stirred for 16 hrs at RT. The mixture was concentrated under reduced pressure and acidify to pH = 3 by addition of HCl 1N. The hydroxy diacid was extracted with AcOEt. The organic layer was dried over MgSO₄ and the solvent removed under reduced pressure to give the desired 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid (3.66 g, 85% yield).

¹H-NMR; delta (CH₃OD), 7.07 (2H, d, J = 8.6Hz), 6.79 (2H, d, J=8.6Hz), 4.23 (1H, d, J=5.8 Hz), 3.98 (2H, q, J = 7.0Hz), 2.76-2.81 (1H, m), 2.53-2.59 (2H, m), 1.55-1.72 (4H, m), 1.35 (3H, t, J=7.0 Hz).

LRMS: +ve ion 319 (M+Na); -ve ion 295 (M-H).

Step E: 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid.

To a solution of 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid (3.66 g, 12.3 mmol) in acetone (50 ml) under an inert atmosphere were added dimethoxy propane (2.58 ml, 21 mmol, 1.7 eq.) and copper chloride (165 mg, 1.2 mmol, 0.1 eq.). The reaction mixture was stirred at RT for 16 hrs. The solvent was then removed under vacuum to give 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid (4.03 g, 97% yield).

¹H-NMR; delta (CDCl₃), 7.08 (2H, d, J = 8.5Hz), 6.82 (2H, d, J = 8.5Hz), 4.48 (1H, d, J = 4.8Hz), 4.01 (2H, q, J = 7.0Hz), 2.91-2.98 (1H, m), 2.54-2.64 (3H, m), 1.23-2.20 (4H, m), 1.58 (3H, s), 1.53 (3H, s) and 1.40 (3H, t, J = 7.0Hz).

LRMS: +ve ion 359 (M+Na); -ve ion 335 (M-H).

Step F. 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid pentafluorophenyl ester.

To a cold (0°C) solution of 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid (4.03g, 12 mmol) and pentafluoro phenol (2.43 g, 13.2 mmol, 1.1 eq.) in CH₂Cl₂ (50 ml) was added WSC (2.54 g, 13.2 mmol, 1.1 eq.). The reaction mixture was allowed to warm to RT overnight. CH₂Cl₂ was removed under vacuum and the resulting crude reaction mixture was dissolved in AcOEt (200 ml). The organic layer was washed with water (50 ml), NaHCO₃ sat (20 ml) and finally with brine (20 ml). Solvent was removed under reduced pressure to give an oil which was purified by flash chromatography to furnish the expected 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid pentafluorophenyl ester (3.94 g, 65% yield).

1H-NMR; delta (CDCl_3), 7.09 (2H, d, $J = 8.4\text{Hz}$), 6.83 (2H, d, $J = 8.4\text{Hz}$), 4.56 (1H, d, $J = 6.0\text{Hz}$), 4.01 (2H, q, $J = 7.0\text{Hz}$), 3.20-3.28 (1H, m), 2.64 (2H, t, $J = 7.6\text{Hz}$), 1.98-2.08 (2H, m), 1.70-1.86 (2H, m), 1.62 (3H, s), 1.57 (3H, s) and 1.40 (3H, t, $J = 7.0\text{Hz}$).

Step G. 2R-[3-(4-Ethoxy-phenyl)-propyl]-N₁-[1S-(5-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,2-dimethyl-propyl]-[1,3]dioxolan-4S-one

To a solution of 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid pentafluorophenyl ester (150 mg, 0.30 mmol) in CH_2Cl_2 (10 ml) was added 2,2-dimethyl-1S-(5-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl)-propylamine (100mg, 0.42 mmol, 1.4 eq.). The reaction mixture was stirred for 16 hrs and the solvent was removed under vacuum. The crude was taken-up in AcOEt (70 ml) and washed with water (10 ml), then with Na_2CO_3 (10 ml) and finally with brine (10 ml). The solvent was dried over MgSO_4 and removed under reduced pressure to give the desired 2R-[3-(4-Ethoxy-phenyl)-propyl]-N₁-[1S-(5-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,2-dimethyl-propyl]-[1,3]dioxolan-4S-one (82 mg, 33% crude).

1H-NMR; delta (CDCl_3), 7.88 (1H, m), 7.62 (1H, m), 7.20 (1H, m), 6.95 (2H, d, $J = 8.4\text{Hz}$), 6.71 (2H, d, $J = 8.4\text{Hz}$), 6.55 (1H, d, $J = 9.7\text{Hz}$), 5.19 (1H, d, $J = 9.7\text{Hz}$), 4.56 (1H, d, $J = 6.4\text{Hz}$), 3.95 (2H, q, $J = 7.0\text{Hz}$), 2.64 (3H, bm), 1.84 (2H, m), 1.70 (2H, m), 1.62 (3H, s), 1.54 (3H, s), 1.38 (3H, t, $J = 6.9\text{Hz}$) and 1.02 (9H, s).

LRMS: +ve ion 556.0 ($M+H$).

Step H. 2R-[3-(4-Ethoxy-phenyl)-propyl]-N₁-[1S-(5-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,2-dimethyl-propyl]-3S,N₄-dihydroxy-succinamide

To a solution of 2R-[3-(4-Ethoxy-phenyl)-propyl]-N₁-[1S-(5-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-2,2-dimethyl-propyl]-[1,3]dioxolan-4S-one (82 mg, 0.15 mmol) in *i*-PrOH (5 ml), was added an aqueous solution of hydroxylamine (50%, 48 μl , 0.7 mmol, 5 eq.). The reaction mixture was allowed to stir at RT

for 16 hrs. The solvent was removed under reduced pressure to yield an oil which was purified by preparative reverse phase chromatography to give the required product (25.3mg, 32%).


1H-NMR; delta(CH₃OD), 1H-NMR; delta(CH₃OD), 7.86 (2H, m), 7.25 (1H, dd, J=3.8Hz), 6.83 (2H, d, J=8.6Hz), 6.54 (2H, d, J=8.6Hz), 5.14 (1H, s), 4.03 (1H, d, J=7.6Hz), 3.87 (2H, q, J=6.96), 2.88 (1H, m), 2.45 (2H, bm), 1.53 (4H, bm), 1.33 (3H, t, J=7.0Hz) and 1.06 (9H, s).

LRMS: +ve ion 553.2 (M+Na); -ve ion 529.2 (M-H)

The compounds of Examples 4-17 were prepared by the method of Example 1 by parallel synthesis, using the appropriate acid chloride in Step D. The products were purified by preparative HPLC:

Example 4


2S-Hydroxy-3R-[1S-(5-isopropyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS: +ve ion 407 (M+Na); -ve ion 383 (M-H)

Example 5


2S-Hydroxy-3R-[1S-(5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 431 (M+Na), -ve ion 407 (M-H).

Example 6


2S-Hydroxy-3R-[1S-(5-cyclopentylmethyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 425 (M+H), -ve ion 423 (M-H).

Example 7


2S-Hydroxy-3R-[1S-(5-thiopen-2-ylmethyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 461 (M+Na), -ve ion 437 (M-H).

Example 8


2S-Hydroxy-3R-[1S-(5-ethyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 393 (M+Na), -ve ion 369 (M-H).

Example 9


2S-Hydroxy-3R-[1S-(5-cyclopentyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 411 (M+H), -ve ion 409 (M-H).

Example 10


2S-Hydroxy-3R-[1S-(5-benzyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 433 (M+H), -ve ion 431 (M-H).

Example 11


2S-Hydroxy-3R-[1S-(5-isobutyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 421 (M+Na), -ve ion 397 (M-H).

Example 12


2S-Hydroxy-3R-[1S-(5-*tert*-butyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 421 (M+Na), -ve ion 397 (M-H).


Example 13

2S-Hydroxy-3R-[1S-(5-thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 425 ($M+H$), -ve ion 423 ($M-H$).


Also prepared, the diastereomer 2R-hydroxy-3R-[1S-(5-thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



$M+H = 425.1$, $M+Na = 447.1$, $M-H = 423.0$.

Example 14


2S-Hydroxy-3R-[1S-(5-(2,2-dimethyl-propyl)-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 435 ($M+Na$), -ve ion 411 ($M-H$).

Example 15


2S-Hydroxy-3R-[1S-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 433 ($M+H$), -ve ion 431 ($M-H$).

Example 16


2S-Hydroxy-3R-[1S-(5-cyclopropyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



LRMS; +ve ion 405 (M+Na), -ve ion 381 (M-H).

Example 17

2S-Hydroxy-3R-[1S-(5-methyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid




1H-NMR; delta(CH₃OD), 8.26 (1H, d, J=9.4Hz), 5.02 (1H, d, J=9.5Hz), 4.02 (1H, d, J=6.4Hz), 2.89 (1H, m), 2.57 (3H, s), 1.61 (1H, m), 1.44 (1H, m), 1.22 (1H, m), 1.00 (9H, s)
 13 C-NMR; delta (CH₃OD), 178.6, 176.1, 171.9, 170.7, 73.5, 55.6, 49.5, 39.9, 36.2, 27.6, 26.6, 24.2, 22.7 and 12.4.
 LRMS; +ve ion 379 (M+Na), -ve ion 355 (M-H).

The compounds of Examples 18-19 were prepared by the method of Example 2, by using the appropriate nitrile in Step C and/or the appropriate amino acid residue in Step A:

Example 18


2S-Hydroxy-3R-[1S-(3-isopropyl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-5-methyl hexanohydroxamic acid



1H-NMR; delta(CH₃OD), 5.12 (1H, s), 3.98 (1H, d, J = 7.5Hz), 3.06 (1H, m), 2.92 (1H, m), 1.61 (1H, m), 1.43 (1H, m), 1.31 (6H, d, J = 6.9Hz), 1.14 (1H, m), 1.03 (9H, s), 0.89(3H, d, J = 6.7Hz), 0.81(3H, d, J = 6.8Hz).
 13 C-NMR; delta (CH₃OD), 179.7, 176.6, 176.5, 172.0, 73.7, 56.9, 49.2, 39.5, 36.5, 28.3, 27.3, 24.5, 22.3, 21.2 and 21.1.
 LRMS; +ve ion 385 (M+H), -ve ion 383 (M-H).

Example 19

2S,N₁-Dihydroxy-3R-isobutyl-N₄-[2-methyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-succinamide



1H-NMR; delta(CH₃OD), 8.05 (2H, m), 7.52 (3H, m), 5.14 (1H, d, J = 7.2Hz), 4.00 (1H, d, J = 7.7Hz), 2.91 (1H, m), 2.36 (1H, m), 1.63 (1H, m), 1.54 (1H, m), 1.16 (1H,m), 1.09 (3H, d, J = 6.8Hz), 1.00 (3H, d, J = 6.8Hz), 0.95(3H, d, J = 6.3Hz), 0.84(3H, d, J = 6.3Hz).


¹³C-NMR; delta (CH₃OD), 181.0, 176.8, 172.0, 169.9, 132.9, 130.5, 128.7, 128.4, 73.7, 54.3, 49.6, 39.5, 33.3, 27.2, 24.4, 22.5, 19.8 and 19.4.

LRMS; +ve ion 427 (M+Na), -ve ion 403 (M-H).

The compounds of Examples 20-23 were prepared by the method of Example 2, by using the appropriate nitrile in Step C and/or the appropriate amino acid residue in Step A. The synthesis to the appropriate chiral succinate in Step E is detailed within WO 94/21625.

Example 20

2S-Allyl-5-methyl-3R-[2-phenyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-ethylcarbamoyl]-hexanohydroxamic acid




¹H-NMR; delta (CH₃OD), 9.13 (1H, d, J = 8.26Hz), 8.05 (2H, m), 7.55 (3H, m), 7.25 (5H, m), 5.66 (1H, m), 5.45 (1H, m), 4.90 (2H, m), 4.50 (1H,s) 3.51 (1H, dd, J = 13.92, 4.84Hz), 3.17 (1H, dd, J = 13.92, 10.90Hz), 2.50 (1H, m), 2.0 (2H, m), 1.50 (3H, m), 1.0 (3H, d, J = 6.5Hz), 0.96 (3H, d, J = 6.6Hz).

¹³C-NMR; delta (CH₃OD), 181.0, 177.0, 172.7, 138.0, 136.5, 133., 130.8, 130.6, 130.5, 130.1, 128.7, 128.7, 117.7, 48.4, 48.3, 42.1, 39.5, 36.2, 27.1, 24.9 and 22.0.

Example 21


2S-Allyl-5-methyl-3R-[2-phenyl-1S-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-ethylcarbamoyl]-hexanohydroxamic acid



¹H-NMR; delta (DMSO), 10.28 (1H, s), 8.64 (1H, d, J=6.2Hz), 8.64 (1H, br s), 7.25 (5H, m), 5.45 (2H, m), 4.51 (1H, m), 4.30 (2H, m), 3.15 (1H, m), 2.85 (2H, m), 2.20 (1H, dt, J=10.6, 3.12Hz), 1.70 (2H, m), 1.25 (6H, d, J=6.91Hz), 0.70 (1H, m), 0.52 (3H, d, J=6.4Hz), 0.48(3H, d, J=6.4Hz).
¹³C-NMR; delta (MEOD), 179.0, 175.6, 175.5, 171.3, 136.6, 135.0, 129.2, 128.6, 127.3, 116.4, 48.7, 46.9, 40.6, 38.1, 34.8, 26.9, 25.6, 23.5, 20.7 and 19.9.

Example 22

2S-Allyl-5-methyl-3R-[2-phenyl-1S-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethylcarbamoyl]-hexanohydroxamic acid




¹H-NMR; delta (CH₃OD), 8.98 (1H, d, J=8.41Hz), 7.27 (5H, m), 5.51 (2H, m), 4.85 (2H, m), 3.41 (1H, dd, J=14.0, 5.0Hz), 3.14 (1H, dd, J=14.0, 10.97Hz), 2.47 (1H, dt, J=11.0, 3.25Hz), 2.16 (3H, s), 2.00 (1H, dt, J=11.40, 3.30Hz), 1.80 (1H, m), 1.15 (1H, m), 0.98 (3H, d, J=6.6Hz), 0.92 (3H, d, J=6.6Hz).

¹³C-NMR; delta (CH₃OD), 172.62, 168.27, 133.59, 132.07, 126.34, 125.66, 124.28, 113.36, 45.19, 44.04, 43.95, 37.61, 35.15, 31.75, 22.72, 20.44, 17.59 and 7.36.

Example 23

2S-Allyl-3R-[2,2-dimethyl-1S-(3-methyl-[1,2,4]oxadiazol-5-yl)-propylcarbamoyl]-5-methyl-hexanohydroxamic acid




1H-NMR; delta (CH₃OD), 8.81 (1H, d, J=8.59Hz), 7.65 (1H, m), 5.70 (1H, m), 5.15 (1H, d, J=8.62Hz), 4.95 (2H, m), 2.60 (1H, dt, J=11.10, 3.16Hz), 2.39 (3H, s), 1.38 (1H, dt, J=13.10, 3.33Hz), 1.31 (1H, m), 0.98 (1H, m), 0.98 (9H,s), 0.86(3H, d, J=6.6Hz), 0.84(3H, d, J=6.6Hz).

The compound of Example 24 was prepared by the method of Example 2.
The synthesis to the appropriate chiral succinate in Step E is detailed within
WO 95/19956

Example 24

3R-[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylcarbamoyl]-5-methyl-hexanohydroxamic acid




LRMS; +ve ion 403.5 (M+H), -ve ion 401.3 (M-H).

The compound of Example 25 was prepared by the method of Example 2, by using the appropriate nitrile in Step C and/or the appropriate amino acid residue in Step A. The synthesis to the appropriate chiral succinate in Step E is detailed within WO 97/02239.

Example 25

2S-Methoxy-5-methyl-3R-[1S-(3-methyl-[1,2,4]oxadiazol-5-yl)-2-phenyl-ethylcarbamoyl]-hexanohydroxamic acid




¹H-NMR; delta (CH₃OD), 7.14 (5H, m), 5.34 (1H, m), 3.38 (1H, d, J=9.68Hz), 3.20 (2H, m), 3.02 (3H, s), 2.65 (1H, m), 2.22 (3H, s), 1.35 (2H, m), 0.90 (1H, m), 0.73 (3H, d, J=6.55Hz), and 0.70 (3H, d, J=6.57Hz).

The compounds of Example 26 and 27 were prepared by the method of Example 2. The synthesis to the appropriate chiral succinate in Step E is detailed within WO 92/13831 using methods analogous to those described in WO 95/32944.

Example 26

3R-[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylcarbamoyl]-heptadecanoic acid




1H-NMR; delta(CH₃OD), 8.05 (2H, m), 7.49 (3H, m), 5.22 (1H, s), 2.93 (1H, m), 2.65 (1H, dd, J=9.8,16.7Hz), 2.38 (1H, dd, J=4.6,16.6Hz), 1.52 (1H, m), 1.43 (1H, m), 1.26 (24H, m), 1.10 (9H, s) and 0.89 (3H, m).

LRMS; +ve ion 528.4 (M+H).

Example 27

3R-[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propylcarbamoyl]-nonadecanoic acid




LRMS; +ve ion 556.2 (M+H).

The compound of Example 28 was prepared by the method of Example 1. The synthesis to the appropriate chiral succinate in Step H is detailed within WO 92/13831 using methods analogous to those described in WO 95/32944.

Example 28

6-(4-Chloro-phenyl)-3R-[2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-hexanoic acid




¹H-NMR; delta(CH₃OD), 8.07 (2H, m), 7.61 (3H, m), 6.93 (4H, m), 5.15 (1H, s), 2.94 (1H, m), 2.5 (4H, m), 1.5 (4H, m) and 1.07 (9H, s).

¹³C-NMR; delta (CH₃OD), 178.0, 177.1, 142.6, 134.6, 132.7, 131.0, 130.8, 129.5, 129.4, 125.7, 55.7, 43.8, 39.0, 36.3, 36.1, 34.1, 30.3 and 27.4.

LRMS; +ve ion 506.2 (M+Na), -ve ion 482.4 (M-H).

Also prepared, the diastereomer 6-(4-Chloro-phenyl)-3R-[2,2-dimethyl-1R-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-hexanoic acid




$M+H = 485$, $M+Na = 507.2$, $M-H = 482.6$.

The compounds of Examples 29 and 30 were prepared by the method of Example 1.

Example 29


3R-[2,2-Dimethyl-1S-(5-thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanoic acid



1H -NMR; δ (CH₃OD), 7.95 (1H, m), 7.87 (1H, d, $J = 5.0$ Hz), 7.28 (1H, m), 5.15 (1H, s), 4.18 (2H, d, $J = 6.4$ Hz), 2.94 (1H, m), 1.68 (1H, m), 1.48 (1H, m), 1.31 (1H, m), 1.06 (9H, s), 0.88 (3H, d, $J = 6.4$ Hz) and 0.82 (3H, d, $J = 6.5$ Hz).
LRMS; -ve ion 408.2 ($M-H$).

Example 30

3R-[1S-(5-Furan-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanoic acid




1H-NMR; delta (CH₃OD), 7.88 (1H, s), 7.45 (1H, d, J = 3.6Hz), 6.74 (1H, m), 5.15 (1H, s), 4.18 (2H, d, J = 6.4Hz), 2.91 (1H, m), 1.65 (1H, m), 1.50 (1H, m), 1.31 (1H, m), 1.06 (9H, s), 0.88 (3H, d, J = 6.4Hz) and 0.82 (3H, d, J = 6.5Hz).
LRMS; -ve ion 392.2 (M-H).

The compounds of Example 31 and 32 were prepared by the method of Example 2. The synthesis to the appropriate chiral succinate in Step E is detailed within WO 94/02446 using the appropriate cinnamyl bromide or cyclopentylmethyl iodide instead of the methallyl iodide as detailed in the aforementioned patent.

Example 31

N₄-[2,2-Dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-2S,N₁-dihydroxy-3R-(3-phenyl-allyl)-succinamide




¹H-NMR; delta(CH₃OD), 7.95 (2H, d, J=7.2Hz), 7.53 (1H, m), 7.48 (2H, m), 7.09 (2H, d, J=6.4Hz), 6.91 (3H, m), 6.31 (1H, d, J=15.8Hz), 6.04 (1H, m), 5.26 (1H, s), 4.14 (1H, d, J=7.6Hz), 3.02 (1H, m), 2.46 (1H, m), 2.37 (1H, m) and 1.07 (9H, s).

¹³C-NMR; delta (CH₃OD), 179.8, 175.9, 172.0, 169.6, 138.8, 134.0, 132.8, 130.4, 129.7, 128.9, 128.4, 128.4, 127.3, 73.2, 56.5, 51.3, 36.8 and 34.0.

LRMS; +ve ion 501.2 (M+Na), -ve ion 477.4 (M-H).

Example 32

2R-Cyclopentylmethyl-3S,N4-dihydroxy-N₁-[1S-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-2,2-dimethyl-propyl]-succinamide




¹H-NMR; delta(CH₃OD), 5.13 (1H, s), 3.99 (1H, d, J=7.7Hz), 3.06 (1H, m), 2.87 (1H, m), 1.83 (1H, m), 1.72 (1H, m), 1.63-1.39 (6H, bm), 1.31 (6H, d, J=6.9Hz), 1.27 (1H, m), 1.03 (9H, s) and 1.02 (2H, m).

¹³C-NMR; delta (CH₃OD), 179.6, 176.6, 176.5, 172.0, 73.6, 56.8, 50.8, 39.6, 36.7, 36.5, 34.7, 33.6, 28.3, 27.2, 26.5 and 21.2.
 LRMS; +ve ion 411.2 (M+H), -ve ion 409.6 (M-H).

The compounds of Examples 33 - 35 were prepared by the method of Example 3 using the appropriate aryl bromide in Step B.

Example 33

2R-[3-(3,5-Bis-trifluoromethyl-phenyl)-propyl]-N₁-[2,2-dimethyl-1S-(5-thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-propyl]-3S,N₄-dihydroxy-succinamide




¹H-NMR; delta(CH₃OD), 8.38 (1H, d, J=9.4Hz), 7.86 (1H, s), 7.75 (3H, bs), 7.4 (1H, d, J=3.5Hz), 6.7 (1H, m), 5.12 (1H, d, J=9.4Hz), 4.26 (1H, d, J=4.0Hz), 2.8 (3H, bm), 1.8 (4H, bm) and 1.0 (9H, s).

LRMS; +ve ion 623.2 (M+H), -ve ion 621.0 (M-H).

Example 34

2R-[3-(3,5-Bis-trifluoromethyl-phenyl)-propyl]-N₁-[1S-(5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propyl]-3S,N₄-dihydroxy-succinamide




¹H-NMR; delta(CH₃OD), 8.38 (1H, d, J=9.4Hz), 7.86 (1H, s), 7.75 (3H, bs), 7.4 (1H, d, J=3.5Hz), 6.7 (1H, m), 5.12 (1H, d, J=9.4Hz), 4.26 (1H, d, J=4.0Hz), 2.8 (3H, bm), 1.8 (4H, bm) and 1.0 (9H, s).

LRMS; +ve ion 629.4 (M+Na), -ve ion 605.4 (M-H).

Example 35

2R-[3-(4-Ethoxy-phenyl)-propyl]-N₁-[1S-(5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-2,2-dimethyl-propyl]-3S,N₄-dihydroxy-succinamide




¹H-NMR; delta(CH₃OD), 7.86 (2H, m), 7.25 (1H, dd, J=3.8Hz), 6.83 (2H, d, J=8.6Hz), 6.54 (2H, d, J=8.6Hz), 5.14 (1H, s), 4.03 (1H, d, J=7.6Hz), 3.87 (2H, q, J=6.96,14.0Hz), 2.88 (1H, m), 2.45 (2H, bm), 1.53 (4H, bm), 1.33 (3H, t, J=7.0Hz) and 1.06 (9H, s).

LRMS; +ve ion 515.2 (M+H), -ve ion 513.2 (M-H).

The compound of Examples 36 was prepared by the method of Example 2. The synthesis to the appropriate chiral succinate in Step E is detailed within WO 01/10834.

Example 36

3-Cyclopentyl-N-[2,2-dimethyl-1S-(3-phenyl-[1,2,4]oxadiazol-5-yl)-propyl]-2R-[(formyl-hydroxy-amino)-methyl]-propionamide



¹H-NMR; delta(CH₃OD), 8.26 (0.3H, s), 8.05 (2H, d, J=6.9Hz), 7.84 (0.7H, s), 7.52 (3H, m), 5.20 (1H, m), 3.75 (1H, m), 3.63 (0.3H, dd, J=13.9, 5.5Hz), 3.43 (0.7H, dd, J=14.2, 4.6Hz), 3.18 (0.7H, m), 3.00 (0.3H, m), 1.92 (1H, m), 1.47 (8H, m), 1.10 (3H, s), 1.08 (6H, s) and 0.98 (2H, m).


¹³C-NMR; delta (CH₃OD), 179.9, 176.9, 176.6, 169.3, 163.8, 159.2, 132.5, 130.0, 129.6, 128.9, 128.3, 127.9, 56.8, 56.7, 53.9, 50.3, 44.8, 44.6, 39.1, 38.9, 37.9, 37.7, 35.9, 35.8, 34.1, 33.4, 33.3, 26.9, 26.1 and 25.9.

LRMS; +ve ion 451 (M+Na), -ve ion 427 (M-H).

The compound of Example 37 was prepared by the method of Example 1. The synthesis to the appropriate chiral succinate in Step E is detailed within WO 01/10834.

Example 37

3-Cyclopentyl-N-[2,2-dimethyl-1S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propyl]-2R-[(formyl-hydroxy-amino)-methyl]-propionamide



¹H-NMR; delta(CH₃OD), 8.49 (0.6H, d, J=8.7Hz), 8.37 (0.4H, d, J=8.1Hz), 8.28 (0.4H, s), 8.14 (2H, m), 7.85 (0.6H, s), 7.65 (1H, m), 7.59 (2H, m), 4.81 (1H, s), 3.79 (1H, m), 3.63 (0.4H, m), 3.43 (0.6H, m), 3.13 (0.6H, m), 2.97 (0.4H, m), 1.55 (9H, m), 1.08 (3H, s), 1.07 (6H, s) and 1.04 (2H, m).
¹³C-NMR; delta (CH₃OD), 176.6, 171.6, 164.2, 159.7, 134.6, 132.8, 130.8, 130.3, 129.4, 125.7, 69.5, 56.0, 54.3, 50.8, 45.4, 45.3, 40.6, 39.5, 38.3, 38.2, 35.9, 34.5, 33.8, 33.7, 32.0, 27.5, 26.4 and 26.3.
LRMS; +ve ion 429 (M+H).

Biological Results

A. Enzyme Inhibition Assays

Compounds of the invention were tested to assess their activities as inhibitors of MMP9 and MMP12.

MMP9 Assay Protocol

Compounds were tested for inhibitory activity against 92kDa gelatinase (MMP9) in an assay using a coumarin-labelled peptide substrate, (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)-Ala-Arg-NH₂ (McaPLGLDpaAR) (Knight et al, FEBS Lett. 1992; 263-266).

Stock solutions were made up as follows:

Assay Buffer: 100mM Tris-HCl pH 7.6 containing 100mM NaCl, 10mM CaCl₂, and 0.05% Brij 35

Substrate: 0.4mM McaPLGLDpaAR (from Bachem) (0.437mg/ml) stock solution in 100%

DMSO (stored at -20°C). Dilute to 8μM in assay buffer.

Enzyme: Recombinant human 92kDa gelatinase (MMP-9; APMA (4-aminophenyl

mercuric acetate) -activated if necessary) appropriately diluted in assay buffer.

Test Compounds were prepared initially as 10mM compound solution in 100% DMSO, diluted to 1mM in 100% DMSO, then serially diluted 3-fold in 100% DMSO across columns 1-10 of a 96-well microtitre plate Assay concentration range, 100μM (column 1) to 5.1nM (column 10)

The assay was performed in a total volume of 100μl per well in 96-well microtitre plates. Activated enzyme (20μl) was added to the wells followed by 20μl of assay buffer. Appropriate concentrations of test compounds dissolved

in 10 μ l of DMSO were then added followed by 50 μ l of McaPLGLDpaAR (8 μ M, prepared by dilution of DMSO stock in assay buffer). For each assay ten concentrations of test compound were examined in duplicate. Control wells lack either enzyme or test compound. The reactions were incubated at 37°C for 2 hours. The fluorescence at 405nm was measured immediately with an SLT Fluostar fluorometer (SLT Lab Instruments GmbH, Grödig, Austria) using 320nm excitation, without stopping the reaction.

The effect of the test compound was determined from the dose response curve generated by the 10 duplicate concentrations of inhibitor. The IC₅₀ (the concentration of compound required to give a 50% decrease in enzyme activity) was obtained by fitting data to the equation, $Y = a + ((b - a) / (1 + (c/X)^d))$. (Y = inhibition achieved for a particular dose; X = the dose in nM; a = minimum y or zero % inhibition; b = maximum y or 100% inhibition; c = is the IC₅₀; d = is the slope). The result was rounded to one significant figure.

MMP12 Assay protocol

Compounds were tested for inhibitory activity against metalloelastase (MMP12) in an assay using a coumarin-labelled peptide substrate, (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)-Ala-Arg-NH₂ (McaPLGLDpaAR) (Knight et al, FEBS Lett. 1992; 263-266). The protocol for this assay was as described for the MMP9 assay above.

MMP1 Assay protocol

Compounds were tested for inhibitory activity against collagenase (MMP1) in an assay using a coumarin-labelled peptide substrate, (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)-Ala-Arg-NH₂ (McaPLGLDpaAR) (Knight et al, FEBS Lett. 1992; 263-266). The protocol for this assay was as described for the MMP9 assay above.

Results:

Key to biological data

Range	A	< 100nM
	B	100 – 1000nM
	C	1000 – 10,000nM
	D	>10,000nM

Example Number	MMP9 IC50(nM)	MMP12 IC50(nM)	MMP1 IC50(nM)
1	B	A	B
2	B	A	B
3	A	A	D
4	B	A	B
5	B	A	B
6	C	A	B
7	C	B	C
8	B	A	B
9	C	A	B
10	C	A	C
11	C	A	C
12	B	A	B
13	B	A	B
14	C	A	C
15	B	A	B
16	B	A	B
17	C	A	B
18	B	A	B
19	B	A	B
20	A	A	B
21	A	A	B
22	Not tested	Not tested	A
23	A	A	B
24	C	A	C
25	B	A	B
26	D	D	Not tested
27	D	D	Not tested
28	Not tested	D	Not tested
29	C	B	C
30	D	C	D
31	D	B	D
32	A	A	A
33	D	B	D
34	D	D	D
35	A	A	D

These results show that in general, the compounds tested were active as inhibitors of MMP12, with certain examples showing selective inhibition of both MMP-9 and 12 relative to MMP-1.

B. CCl₄-induced liver fibrosis model

Carbon tetrachloride (CCl₄) induces liver fibrosis when administered intraperitoneally (Bulbena O, Culat J, Bravo ML., Inflammation 1997 Oct; 21(5):475-88). Compounds of the invention can be evaluated for their ability to prevent the CCl₄ -induced formation of fibrotic tissue.

Animals

Male Sprague-Dawley rats, 7 weeks old, weight approx. 300 g from Charles River/Iffa-Crédo, St-Germain/l'Arbresle, France.

Rats were acclimatised for 5 days before commencing experiments, in air-conditioned rooms, 2 animals per cage, Temperature: 22°C ± 2, Relative humidity: 55% ± 10 Light: 12 hour cycle (7 a.m. - 7 p.m.), Cage: Makrolon® cage 42.5x26.6x15 on each fitted with a stainless steel cover-feed rack.

The study involved the following groups of 8 animals each, as indicated below.

Group 1: "Sham" animals received CCl₄ vehicle (i.p.) and once daily, the vehicle of test substance (s.c.)

Group 2: Positive control group received CCl₄ (i.p.), and once daily, the vehicle of the test substance (s.c.)

Group 3: Experimental group received CCl₄ (i.p.), and once daily, 2 mg/kg s.c. of the compound of Example 13.

Group 4: Experimental group received CCl₄ (i.p.), and once daily, 10 mg/kg s.c. of the compound of Example 13.

Group 5: Experimental group received CCl₄ (i.p.) and once daily, 20 mg/kg s.c. of the compound of Example 13.

Rats were labelled on their tails. The labels were checked and renewed, if necessary, after every CCl₄ injection.

Procedure

CCl₄ (Prolabo) in olive oil was administered every 3 days for three weeks by intraperitoneal injection (0,25 ml CCl₄/kg body weight, diluted in oil 1:1 vol:vol for a total volume of 0.5 ml/kg). Animals were weighed daily. If body weight decreased by more than 10% of the initial weight, the animal was excluded from the study.

Vehicles and compound were used as follows :

- CCl₄ was administered in olive oil (prolabo) at a 1:1 dilution;
- The compound of Example 13 was suspended in 0.25 % Tween-80 and 0.25% carboxymethylcellulose in sterile 0.9% NaCl. The solution was kept at 4 °C throughout the experiment and used each day to prepare the suspensions.

The compound of Example 13 was administered daily by subcutaneous (s.c.) injection at a volume of administration of 5 ml/kg. Groups 1 and 2 were dosed s.c. with 5 ml/kg of vehicle. Freshly prepared solutions were used on each day of the experiment. Administrations were carried out each day at the same time.

The treatment of groups of this study was started for each animal at the time of the first CCl₄ administration and was continued for 21 consecutive days. The last administration of test substances or vehicle was done 1 day before the sacrifice of the animals.

Results

Death was reported for 16 animals. Date and supposed cause are reported in Table 1.

Serum enzyme levels

Animals were killed 21 days following the first CCl₄ administration by isofurane inhalation. Blood was withdrawn individually at the time of sacrifice, i.e. one day after the last administration of test substance or vehicle. Blood was centrifuged at 4°C. Plasma was carefully collected and aliquoted in 3 fractions. Plasma aspartate amino transferase (ASAT) and alanine amino transferase (ALAT) levels were measured in order to assess liver necrosis. Increased ASAT and ALAT levels in serum are associated with liver impairment. Average ASAT and ALAT levels for control animals and those treated with the compound of Example 13 at three different dosages are shown in Figure 1 (Y-axis is units of enzyme activity per litre blood, IU/L). Subcutaneous treatment with the compound of Example 13 clearly decreases ASAT and ALAT levels compared to animals treated with vehicle. This demonstrates that the compound of Example 13 has a protective effect on the liver.

Histological evaluation of liver fibrosis

Liver fibrosis was evaluated by measuring the area of fibrosis in the liver using microchotomy. Results are reported as percentage area that was fibrotic.

The liver was removed, the three lobes were dissected and samples were removed and either fixed in 10% formaldehyde or frozen at -80 °C.

Liver sections were embedded in paraffin blocks. Sectioning and staining with Sirius red was performed. Quantification of the fibrosis in liver was carried out on a minimum of 3 sections taken from different locations in the liver. The quantitative analysis was performed using an image analyser (Imstar) and the software Morphostar.

Average area percentages of fibrosis in the livers of animals in the different groups were calculated, and the results are shown in Figure 2.

B. IL2-induced peritoneal recruitment of lymphocytes

Administration of IL2 intraperitoneally causes migration of lymphocytes into the intraperitoneal cavity. This is a model for the cellular migration that occurs during inflammation.

Compounds of the invention inhibit IL2-induced lymphocyte recruitment.

Protocol

C3H/HEN mice (Elevage Janvier, France) were intraperitoneally injected with IL2 (Serono Pharmaceutical Research Institute, 20 µg/kg, in saline).

Compounds of the invention were suspended in 0.5% carboxymethylcellulose (CMC)/0.25% tween-20 and were administered by *sc* or *po* route (10 ml/kg) 15 min prior to administration of IL2.

Twenty-four hours after administration of IL2, peritoneal white blood cells were collected by 3 successive lavages of the peritoneal cavity with 5 ml phosphate buffered saline (PBS)-1mM EDTA (+4°C). The suspension was centrifuged (1700g x 10 min at +4°C). The resulting pellet was suspended in 1 ml PBS-1mM EDTA.

Lymphocytes were identified and counted using a Beckman/Coulter counter.

Experimental design

The animals were divided into 5 groups (6 mice each group):

Group 1: (baseline) received 0.5% CMC/0.25% tween-20 (vehicle of compound of the invention) and saline (vehicle of IL2);

Group 2: (control IL2) received 0.5% CMC/0.25% tween-20 and injection of IL2;

Group 3: Experimental group (Compound of the invention Dose 1) received a compound of the invention and injection of IL2;

Group 4: Experimental group (Compound of the invention Dose 2) received a compound of the invention and injection of IL2;

Group 5: Experimental group (Compound of the invention Dose 3) received a compound of the invention and injection of IL2;

Group 6: Reference group received reference compound dexamethasone and injection of IL2

Calculation

Inhibition of lymphocyte recruitment was calculated as follows:

$$\% \text{ inhibition} = \frac{1 - (\text{LyX} - \text{Ly1})}{(\text{Ly2} - \text{Ly1})} \times 100\%$$

Where Ly 1= Number of lymphocytes in group 1 (E3/ μ l), Ly 2= Number of lymphocytes in group 2 (E3/ μ l), Ly X= Number of lymphocytes in group X (3-5) (E3/ μ l)


The dose of compound of the invention required to inhibit lymphocyte recruitment by 50% (ID₅₀) was calculated using a curve-fitting routine. Results are listed in Table 1.

Table 1: ID₅₀ for inhibition of IL2-induced peritoneal recruitment of lymphocytes by compounds of the invention


Example	Dose range or doses (mg/kg)	Route	ID ₅₀ (mg/kg)
dexamethasone	0.1-1	Subcutaneous	0.05
Example 13	0.03, 0.3, 3, 30	Subcutaneous	0.1
Example 13	0.3, 3, 30	Oral	1
Example 5	0.3, 1, 3, 10, 30	Subcutaneous	1

Claims:

1. A compound formula (IA or (IB)



(IA)



(IB)

wherein

W represents HO(C=O)-, HONH(C=O)- or H(C=O)N(OH)-;

X represents -O- or -S-;

R₁ represents

- hydrogen;
- OH or -SH;
- fluoro or chloro;
- CF₃;

(C₁-C₆)alkyl;

(C₁-C₆)alkoxy;

(C₂-C₆)alkenyl;

phenyl or substituted phenyl;

phenyl (C₁-C₆)alkyl or substituted phenyl(C₁-C₆)alkyl;

phenyl (C₂-C₆)alkenyl or substituted phenyl(C₂-C₆)alkenyl

heterocyclyl or substituted heterocyclyl;

heterocyclyl(C₁-C₆)alkyl or substituted heterocyclyl(C₁-C₆)alkyl;

a group BSO_nA- wherein n is 0, 1 or 2 and B is hydrogen or a

(C₁-C₆) alkyl, phenyl, substituted phenyl, heterocyclyl substituted

heterocyclyl, (C₁-C₆)acyl, phenacyl or substituted phenacyl group, and A represents (C₁-C₆)alkylene; -NH₂, (C₁-C₆)alkylamino or di(C₁-C₆)alkylamino; amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, mercapto(C₁-C₆)alkyl or carboxy(C₁-C₆)alkyl wherein the amino-, hydroxy-, mercapto- or carboxyl-group are optionally protected or the carboxyl- group amidated; or a cycloalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one or more substituents selected from C₁-C₆ alkyl, C₂-C₆ alkenyl, halo, cyano (-CN), -CO₂H, -CO₂R, -CONH₂, -CONHR, -CON(R)₂, -OH, -OR, oxo-, -SH, -SR, -NHCOR, and -NHCO₂R wherein R is C₁-C₆ alkyl or benzyl and/or (ii) fused to a cycloalkyl or heterocyclic ring;

R₂ represents a group R₁₀-(X)_n-(ALK)_m wherein

R₁₀ represents hydrogen, or a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C₁-C₁₂)alkyl, (C₁-C₁₂)alkoxy, hydroxy, mercapto, (C₁-C₁₂)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, oxo, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₁₂)alkyl group and

ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages,

X represents -NH-, -O- or -S-, -NR^C or -NCOR^C wherein R^C is a (C₁-C₁₂)alkyl group, and

m and n are independently 0 or 1;

R₃ represents the side chain of a natural or non-natural alpha amino acid;

R₄ represents optionally substituted

C₁-C₆ alkyl,

C₂-C₆ alkenyl,

C₂-C₆ alkynyl,

C₁-C₃ perfluoroalkyl,

cycloalkyl,

cycloalkyl(C₁-C₆ alkyl)-,

cycloalkenyl,

cycloalkenyl(C₁-C₆ alkyl)-,

phenyl,

phenyl(C₁-C₆ alkyl)-,

naphthyl,

non-aryl heterocyclyl,

non-aryl heterocyclyl(C₁-C₆ alkyl)-,

heteroaryl; or

heteroaryl(C₁-C₆ alkyl)-;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

2. A compound as claimed in claim 1 wherein the compound has formula (IA).

3. A compound as claimed in claim 1 wherein the compound has formula (IB).

4. A compound as claimed in any of the preceding claims wherein W is HONH(C=O)-.

5. A compound as claimed in any of the preceding claims wherein X is —O—.

6. A compound as claimed in any of the preceding claims wherein R₁ is

hydrogen, hydroxy, fluoro, chloro, methyl, methoxy, trifluoromethyl, ethyl, n-propyl, allyl, phenylpropyl, cyclopropylmethyl, phenylprop-2-enyl, thienylsulphanyl methyl, thienylsulphinyl methyl, or thienylsulphonyl methyl; or

C₁-C₄ alkyl, eg methyl, ethyl n-propyl or n-butyl, substituted by a phthalimido, 1,2-dimethyl-3,5-dioxo-1,2,4-triazolidin-4-yl, 3-methyl-2,5-dioxo-1-imidazolidinyl, 3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl, 2-methyl-3,5-dioxo-1,2,4-oxadiazol-4-yl, 3-methyl-2,4,5-trioxo-1-imidazolidinyl, 2,5-dioxo-3-phenyl-1-imidazolidinyl, 2-oxo-1-pyrrolidinyl, 2,5-dioxo-1-pyrrolidinyl or 2,6-dioxopiperidinyl, 5,5-dimethyl-2,4-dioxo-3-oxazolidinyl, hexahydro-1,3-dioxopyrazolo[1,2,a][1,2,4]-triazol-2-yl, or a naphththalimido (ie 1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl), 1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl, 1,3-dihydro-1,3-dioxo-2H-pyrrolo[3,4-b]quinolin-2-yl, or 2,3-dihydro-1,3-dioxo-1H-benz[d,e]isoquinolin-2-yl group; or

cyclohexyl, cyclooctyl, cycloheptyl, cyclopentyl, cyclobutyl, cyclopropyl, tetrahydropyranyl or morpholinyl.

7. A compound as claimed in any of claims 1 to 5 wherein R₁ is hydrogen, hydroxy, C₂-C₄ alkenyl or C₁-C₄ alkoxy.

8. A compound as claimed in any of claims 1 to 5 wherein R₁ is hydrogen, hydroxy, fluoro, methoxy, cyclopentyl, n-propyl, or allyl.

9. A compound as claimed in any of claims 1 to 8 wherein R₂ is

C₁-C₁₂ alkyl, C₃-C₆ alkenyl or C₃-C₆ alkynyl;

cycloalkyl(C₁-C₆ alkyl)-;

phenyl(C₁-C₆ alkyl)-, phenyl(C₃-C₆ alkenyl)- or phenyl(C₃-C₆ alkynyl)- optionally substituted in the phenyl ring;

heteroaryl(C₁-C₆ alkyl)-, heteroaryl(C₃-C₆ alkenyl)- or heteroaryl(C₃-C₆ alkynyl)- optionally substituted in the heteroaryl ring;

4-phenylphenyl(C₁-C₆ alkyl)-, 4-phenylphenyl(C₃-C₆ alkenyl)-, 4-phenylphenyl(C₃-C₆ alkynyl)-, 4-heteroarylphenyl(C₁-C₆ alkyl)-, 4-heteroarylphenyl(C₃-C₆ alkenyl)-, 4-heteroarylphenyl(C₃-C₆ alkynyl)-, optionally substituted in the terminal phenyl or heteroaryl ring; or

phenoxy(C₁-C₆ alkyl)- or heteroaryloxy(C₁-C₆ alkyl)- optionally substituted in the phenyl or heteroaryl ring;

10. A compound as claimed in any of claims 1 to 8 wherein R₂ is methyl, ethyl, n- or iso-propyl, n-, iso- or tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-nonyl, n-decyl, prop-2-yn-1-yl, cyclohexylethyl, cyclopentylmethyl, 3-phenylprop-2-yn-1-yl, 3-(2-chlorophenyl)prop-2-yn-1-yl, benzyl phenylpropyl, 4-chlorophenylpropyl, 4-methylphenylpropyl, 4-methoxyphenylpropyl, phenoxybutyl, 3-(4-pyridylphenyl)propyl-, 3-(4-(4-pyridyl)phenyl)prop-2-yn-1-yl, 3-(4-phenylphenyl)propyl-, 3-(4-phenyl)phenyl)prop-2-yn-1-yl or 3-[(4-chlorophenyl)phenyl]propyl-.

11. A compound as claimed in any of claims 1 to 8 wherein R₂ is C₁-C₄ alkyl, 3-8 membered cycloalkyl-C₁-C₄ alkyl- optionally containing 1-3 heteroatoms in the ring selected from N, O and S, or aryl-C₁-C₄ alkyl.

12. A compound as claimed in any of claims 1 to 8 wherein R₂ is benzyl, n-butyl, iso-butyl, n-hexyl, cyclopentylmethyl, 4-ethoxyphenylpropyl or phenylpropyl.

13. A compound as claimed in any of the preceding claims wherein R₃ is C₁-C₆ alkyl, phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 2-, 3-, or 4-hydroxyphenyl, 2-, 3-, or 4-methoxyphenyl, 2-, 3-, or 4-pyridylmethyl, benzyl, 2-, 3-, or 4-hydroxybenzyl, 2-, 3-, or 4-benzyloxybenzyl, 2-, 3-, or 4-C₁-C₆ alkoxybenzyl, or benzyloxy(C₁-C₆alkyl)-; or

the characterising group of a natural α -amino acid, in which any functional group may be protected, any amino group may be acylated and any carboxyl group present may be amidated; or

a group -[Alk]_nR₆ where Alk is a (C₁-C₆)alkyl or (C₂-C₆)alkenyl group optionally interrupted by one or more -O-, or -S- atoms or -N(R₇)- groups [where R₇ is a hydrogen atom or a (C₁-C₆)alkyl group], n is 0 or 1, and R₆ is an optionally substituted cycloalkyl or cycloalkenyl group; or

a benzyl group substituted in the phenyl ring by a group of formula -OCH₂COR₈ where R₈ is hydroxyl, amino, (C₁-C₆)alkoxy, phenyl(C₁-C₆)alkoxy, (C₁-C₆)alkylamino, di((C₁-C₆)alkyl)amino, phenyl(C₁-C₆)alkylamino, the residue of an amino acid or acid halide, ester or amide derivative thereof, said residue being linked via an amide bond, said amino acid being selected from glycine, α or β alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid, and aspartic acid; or

a heterocyclic(C₁-C₆)alkyl group, either being unsubstituted or mono- or di-substituted in the heterocyclic ring with halo, nitro, carboxy, (C₁-C₆)alkoxy, cyano, (C₁-C₆)alkanoyl, trifluoromethyl (C₁-C₆)alkyl, hydroxy, formyl, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, mercapto, (C₁-C₆)alkylthio, hydroxy(C₁-C₆)alkyl, mercapto(C₁-C₆)alkyl or (C₁-C₆)alkylphenylmethyl; or

a group $-CR_aR_bR_c$ in which:

each of R_a , R_b and R_c is independently hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl(C_1-C_6)alkyl, (C_3-C_8)cycloalkyl; or

R_c is hydrogen and R_a and R_b are independently phenyl or heteroaryl such as pyridyl; or

R_c is hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl(C_1-C_6)alkyl, or (C_3-C_8)cycloalkyl, and R_a and R_b together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 5- to 6-membered heterocyclic ring; or

R_a , R_b and R_c together with the carbon atom to which they are attached form a tricyclic ring (for example adamantyl); or

R_a and R_b are each independently (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl(C_1-C_6)alkyl, or a group as defined for R_c below other than hydrogen, or R_a and R_b together with the carbon atom to which they are attached form a cycloalkyl or heterocyclic ring, and R_c is hydrogen, -OH, -SH, halogen, -CN, -CO₂H, (C_1-C_4)perfluoroalkyl, -CH₂OH, -CO₂(C_1-C_6)alkyl, -O(C_1-C_6)alkyl, -O(C_2-C_6)alkenyl, -S(C_1-C_6)alkyl, -SO(C_1-C_6)alkyl, -SO₂(C_1-C_6)alkyl, -S(C_2-C_6)alkenyl, -SO(C_2-C_6)alkenyl, -SO₂(C_2-C_6)alkenyl or a group -Q-W wherein Q represents a bond or -O-, -S-, -SO- or -SO₂- and W represents a phenyl, phenylalkyl, (C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkylalkyl, (C_4-C_8)cycloalkenyl, (C_4-C_8)cycloalkenylalkyl, heteroaryl or heteroarylalkyl group, which group W may optionally be substituted by one or more substituents independently selected from, hydroxyl, halogen, -CN, -CO₂H, -CO₂(C_1-C_6)alkyl, -CONH₂, -CONH(C_1-C_6)alkyl, -CONH(C_1-C_6 alkyl)₂, -CHO, -CH₂OH, (C_1-C_4)perfluoroalkyl, -O(C_1-C_6)alkyl, -S(C_1-C_6)alkyl, -SO(C_1-C_6)alkyl, -SO₂(C_1-C_6)alkyl,

-NO₂, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NHCO(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, phenyl or benzyl.

14. A compound as claimed in any of claims 1 to 12 wherein R₃ is benzyl, phenyl, cyclohexylmethyl, pyridin-3-ylmethyl, tert-butoxymethyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, 1-benzylthio-1-methylethyl, 1-methylthio-1-methylethyl, or 1-mercaptop-1-methylethyl.
15. A compound as claimed in any of claims 1 to 12 wherein R₃ is (C₁-C₄)alkyl or aryl- is (C₁-C₄)alkyl.
16. A compound as claimed in any of claims 1 to 12 wherein R₃ is benzyl, tert-butoxymethyl, iso-propyl, tert-butyl, or iso-butyl.
17. A compound as claimed in any of the preceding claims wherein R₄ is optionally substituted (C₁-C₆)alkyl; (C₃-C₈)cycloalkyl; phenyl; monocyclic heterocyclic; or monocyclic heteroaryl.
18. A compound as claimed in any of claims 1 to 16 wherein R₄ is C₁-C₄ alkyl, aryl, heteroaryl, 3-8 membered cycloalkyl optionally containing 1-3 heteroatoms in the ring selected from N, O and S, aryl-C₁-C₄ alkyl or heteroaryl-C₁-C₄ alkyl.
19. A compound as claimed in any of claims 1 to 16 wherein R₄ is optionally substituted methyl, ethyl, n- or iso-propyl, prop-2-yl, tert-butyl, cyclopropyl, cyclopentyl; phenyl; morpholino; thienyl or furanyl.
20. A compound as claimed in claim 2 wherein R₁ is -OH; W is -C(=O)NHOH, X is -O- and R₃ is tert-butyl.
21. A compound as claimed in claim 2 wherein R₁ is -OH; W is -C(=O)NHOH, X is -O-, R₃ is tert-butyl, and R₂ is C₁-C₁₂ alkyl, or phenyl(C₁-C₁₂)alkyl.

C₁₂ alkyl)- or heteroaryl(C₁-C₆)alkyl)- which are optionally substituted in the phenyl or heteroaryl ring.

22. A compound as claimed in claim 2 wherein R₁ is -OH; W is -C(=O)NHOH, X is -O-, R₃ is tert-butyl, and R₂ is phenylpropyl- or ethoxyphenylpropyl.

23. A compound as claimed in claim 2 wherein R₁ is -OH; W is -C(=O)NHOH, X is -O-, R₃ is tert-butyl, and R₄ is branched C₁-C₁₂ alkyl, cycloalkyl, phenyl, heteroaryl, phenyl(C₁-C₆ alkyl)- or heteroaryl(C₁-C₆)alkyl)-.

24. A compound as claimed in claim 2 wherein R₁ is -OH; W is -C(=O)NHOH, X is -O-, R₃ is tert-butyl, R₂ is ethoxyphenylpropyl and R₄ is phenyl or heteroaryl.

25. A compound as claimed in claim 3 wherein W is -C(=O)NHOH and X is -O-.

26. A compound as claimed in claim 3 wherein W is -C(=O)NHOH, X is -O-, and R₃ is tert-butyl.

27. A compound as claimed in claim 3 wherein W is -C(=O)NHOH, X is -O-, and R₁ is -OH, C₁-C₆ alkoxy, or C₂-C₆ alkenyl.


28. A compound as claimed in claim 3 wherein W is -C(=O)NHOH, X is -O-, R₁ is -OH, C₁-C₆ alkoxy, or C₂-C₆ alkenyl, R₃ is tert-butyl or benzyl and R₄ is isopropyl.

29. A compound as claimed in claim 1 which is the subject of any of the Examples herein.

30. A pharmaceutical or veterinary composition comprising a compound as claimed in any of the preceding claims.

31. A method of treatment or prophylaxis of diseases mediated by MMPs in mammals which method comprises administering to the mammal an effective amount of a compound as claimed in any of claims 1 to 29.
32. A compound as claimed in any of claims 1 to 29 for use in human or veterinary medicine.
33. The use of a compound as claimed in any of claims 1 to 29 in the preparation of a medicament for the treatment or prophylaxis of diseases mediated by MMPs.
34. A method as claimed in claim 31 or the use as claimed in claim 33 wherein the disease is bone resorption, tumour growth or invasion by secondary metastases; rheumatoid arthritis, septic arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, neuroinflammatory disorders, e.g. multiple sclerosis; restenosis; emphysema; fibrotic disease e.g. liver fibrosis and cystic fibrosis; chronic obstructive pulmonary disease; bronchitis; asthma; autoimmune disease; transplant rejection (e.g. graft versus host disease); cystic fibrosis; psoriasis; psoriatic arthritis; degenerative cartilage loss; inflammatory gastric conditions, e.g. Crohn's disease, inflammatory bowel disease, and ulcerative colitis; atopic dermatitis, epidermolysis bullosa; epidermic ulceration; a neuropathy or nephropathy e.g. interstitial nephritis, glomerulonephritis and renal failure; ocular inflammation; liver cirrhosis, Sjogren's syndrome; or an inflammatory condition of the nervous system.
35. A method as claimed in claim 31 or the use as claimed in claim 33 wherein the disease is multiple sclerosis, emphysema, liver fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, Crohn's disease, inflammatory bowel disease, or liver sclerosis.
36. A method as claimed in claim 31 or the use as claimed in claim 33 wherein the disease is hepatitis.


37. A process for the preparation of a compound as claimed in claim 1 in which W is a hydroxamic acid group $\text{HONH}(\text{C=O})-$, which process causing an acid of general formula (IIA) or (IIB)




or an activated derivative thereof to react with hydroxylamine, O-protected hydroxylamine, or an N,O-diprotected hydroxylamine, or a salt thereof, X, R_1 , R_2 , R_3 , and R_4 being as defined in claim 1 except that any substituents in R_1 , R_2 , R_3 , and R_4 which are potentially reactive with hydroxylamine, O-protected hydroxylamine, the N,O-diprotected hydroxylamine or their salts are optionally themselves protected from such reaction, then removing any protecting groups from the resultant hydroxamic acid moiety and from any protected substituents in R_1 , R_2 , R_3 , and R_4 .

38. A process for the preparation of a compound as claimed in claim 1 wherein W is an N-formylhydroxylamino group $\text{H}(\text{C=O})\text{NH}(\text{OH})-$ which process comprises N-formylation of the corresponding compound in which W is $-\text{NH}(\text{OP})$ wherein P is an O-protecting group, then removing the O-protecting group P.

39. A process for the preparation of a compound as claimed in claim 1 wherein W is a carboxylic acid group $-\text{COOH}$, which process comprises: coupling an acid of formula (III) or an activated derivative thereof




with an amine of formula (IVA) or (IVB)



wherein X, R₁ R₂, R₃, and R₄ are as defined in claim 1 except that any substituents in R₁, R₂, R₃, and R₄ which are potentially reactive in the coupling reaction may themselves be protected from such reaction, and R₁₁ represents a hydroxy protecting group, and subsequently removing the protecting group R₁₁ and any protecting groups from R₁ R₂, R₃, and R₄.


1/2

Figure 1 n1 1



2/2

Figure 2



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/00741

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D271/06 C07D285/08 C07D413/04 C07D413/06 A61K31/4245
 A61K31/433 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 23790 A (SMITHKLINE BEECHAM CORPORATION) 8 September 1995 (1995-09-08) the whole document ---	1-38
Y	CHEN J J ET AL: "Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 13, 9 July 1996 (1996-07-09), pages 1601-1606, XP004175762 the whole document ---	1-38
Y	WO 96 33176 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 24 October 1996 (1996-10-24) the whole document ---	1-38
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

8 May 2003

Date of mailing of the international search report

22/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/00741

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2001/021718 A1 (BAILEY S ET AL) 13 September 2001 (2001-09-13) the whole document ----	1-38
A	VU C B ET AL: "Nonpeptidic SH2 Inhibitors of the tyrosine kinase ZAP-70" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 20, 18 October 1999 (1999-10-18), pages 3009-3014, XP004180527 the whole document -----	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 03/00741

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 31 and 34-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 03/00741

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9523790	A 08-09-1995	EP JP WO US	0748313 A1 9509940 T 9523790 A1 5665753 A	18-12-1996 07-10-1997 08-09-1995 09-09-1997
WO 9633176	A 24-10-1996	US AU CA EP JP WO	5703092 A 5665396 A 2218345 A1 0821675 A1 11504015 T 9633176 A1	30-12-1997 07-11-1996 24-10-1996 04-02-1998 06-04-1999 24-10-1996
US 2001021718	A1 13-09-2001	AU BG BR CA EP WO NO TR	1875601 A 106866 A 0016717 A 2395186 A1 1240152 A1 0147901 A1 20023058 A 200201642 T2	09-07-2001 31-03-2003 03-09-2002 05-07-2001 18-09-2002 05-07-2001 23-08-2002 21-11-2002